Qaiser Bashir, MD

Peer-Reviewed Articles

1. Smallbone P, Mendt M, Sackstein R, Tanner MR, Kaur I, Basar R, Rafei H, Daher M, Overman B, Al-Atrash G, Alousi AM, Bashir Q, Hosing CM, Im JS, Kebriaei P, Banerjee P, Patel KP, Zou J, Cao K, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat UR, Qazilbash MH, Rondon G, Saini N, Srour S, Champlin RE, Rezvani K, Shpall EJ, Olson A. Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftment. Cytotherapy 28(3):102010, 2026. e-Pub 2026. PMID: 41396090.
2. Haider AA, Marcoux C, Milton DR, Tanner MR, Bashir Q, Smallbone P, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Mohamedi AH, Siddiqui UR, Aljawai Y, Kebriaei P, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O. Lenalidomide maintenance after delayed or salvage autologous stem cell transplantation. Leuk Lymphoma:1-9, 2026. e-Pub 2026. PMID: 41608977.
3. Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Saeed A, Haider AA, Ramdial J, Irfan S, YagoNieto, Tang G, Aljawai Y, Kebriaei P, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O. Post-transplant outcomes in IgD multiple myeloma:a propensity score-matched analysis. Transplant Cell Ther, 2025. e-Pub 2025. PMID: 41421540.
4. Pasvolsky O, Marcoux C, Milton DR, Haider AA, Tanner MR, Bashir Q, Srour S, Saini N, Smallbone P, Lin P, Ramdial J, Nieto Y, Mohamedi AH, Siddiqui UR, Jamil A, Tang G, Aljawai Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma. Bone Marrow Transplant, 2025. e-Pub 2025. PMID: 41350936.
5. Marcoux, C, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Patel, A, Khan, HN, Ramdial, JL, Nieto, Y, Tang, G, Haider, A, Aljawai, YM, Kebriaei, P, Lee, HC, Ye, JC, Patel, K, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH, Pasvolsky, O. Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant. Transplantation and Cellular Therapy 31(10):804.e1-804.e9, 2025. e-Pub 2025. PMID: 40752590.
6. Smallbone, PI, Shigle, TL, Paslovsky, O, Hosing, C, Alousi, AM, Bashir, Q, Aljawai, YM, Ramdial, JL, Popat, UR, Champlin, RE, Shpall, E, Oran, B. Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome. Haematologica 110(8):1798-1807, 2025. e-Pub 2025. PMID: 40013380.
7. Pasvolsky, O, Marcoux, C, Milton, D, Rafaeli, N, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Mohamedi, A, Deen, AF, Aljawai, YM, Lee, HC, Patel, K, Becnel, M, Kebriaei, P, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous Transplantation. Transplantation and Cellular Therapy 31(8):565.e1-565.e9, 2025. e-Pub 2025. PMID: 40383197.
8. Oran, B, Thall, PF, Alousi, AM, Al-Atrash, G, Mehta, RS, Marin, D, Kebriaei, P, Popat, UR, Bassett Jr, R, Bashir, Q, Im, JS, Olson, AL, Jewell, J, Smallbone, PI, Shpall, E, Champlin, RE. Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant. Haematologica 111(1):149-157, 2025. e-Pub 2025. PMID: 40702903.
9. Pasvolsky, O, Abid, MB, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Jatoi, A, Khan, HN, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Siddiqui, U, Aljawai, YM, Kebriaei, P, Lee, HC, Patel, K, Gaballa, MM, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response. British Journal of Haematology 206(6):1730-1736, 2025. e-Pub 2025. PMID: 40159289.
10. Pasvolsky, O, Marcoux, C, Wang, Z, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Syed, N, Aljawai, YM, Lee, HC, Patel, K, Becnel, M, Ye, JC, Kebriaei, P, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 31(3):166.e1-166.e9, 2025. e-Pub 2025. PMID: 39746546.
11. Bashir, Q, Konopleva, M, Abueg, G, Ramdial, JL, Hosing, C, Srour, S, Alousi, AM, Popat, UR, Nieto, Y, Al-Atrash, G, Champlin, RE, Shpall, E, Qazilbash, MH, Pemmaraju, N. Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm. Leukemia Research Reports 24, 2025. e-Pub 2025. PMID: 40612021.
12. Marcoux, C, Pasvolsky, O, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Ahmed, A, Aljawai, YM, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p. Transplantation and Cellular Therapy 31(1):12.e1-12.e10, 2025. e-Pub 2025. PMID: 39448031.
13. Pasvolsky, O, Ghanem, S, Milton, D, Rauf, M, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Khan, HN, Kebriaei, P, Lee, HC, Patel, K, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 38199987.
14. Pasvolsky, O, Wang, Z, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Kebriaei, P, Aljawai, YM, Khan, HN, Lee, HC, Ye, JC, Patel, K, Thomas, SK, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 38760362.
15. Pasvolsky, O, Marcoux, C, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Lee, J, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Kebriaei, P, Becnel, M, Lee, HC, Patel, K, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39482325.
16. Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Lee HC, Gaballa MR, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades. Transplant Cell Ther 30(8):772.e1-772.e11, 2024. e-Pub 2024. PMID: 38852784.
17. Saengboon, S, Ciurea, SO, Popat, UR, Ramdial, JL, Bashir, Q, Alousi, AM, Chen, J, Rondon, G, Olson, AL, Im, J, Hosing, C, Shpall, E, Champlin, RE, Srour, S. Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies. Blood Advances 8(12):3237-3245, 2024. e-Pub 2024. PMID: 38607399.
18. Alzahrani, K, Pasvolsky, O, Wang, Z, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Lee, HC, Patel, K, Manasanch, EE, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. British Journal of Haematology 204(5):1944-1952, 2024. e-Pub 2024. PMID: 38448009.
19. Pasvolsky, O, Pasyar, S, Bassett Jr, R, Khan, HN, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer 130(9):1663-1672, 2024. e-Pub 2024. PMID: 38127583.
20. Ahmed, S, Bashir, Q, Bassett Jr, R, Ullah, F, Aung, FM, Valdez, B, Alousi, AM, Hosing, C, Kebriaei, P, Khouri, IF, Marin, D, Nieto, Y, Olson, AL, Oran, B, Qazilbash, MH, Rezvani, K, Mehta, RS, Shpall, E, Ciurea, SO, Andersson, BS, Champlin, RE, Popat, UR. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation. American journal of hematology 99(4):562-569, 2024. e-Pub 2024. PMID: 38314663.
21. Marcoux, C, Saliba, RM, Wallis, W, Khazal, SJ, Ragoonanan, D, Rondon, G, Tewari, P, Popat, UR, Oran, B, Olson, AL, Bashir, Q, Qazilbash, MH, Alousi, AM, Hosing, C, Nieto, Y, Al-Atrash, G, Marin, D, Rezvani, K, Khouri, IF, Srour, S, Champlin, RE, Shpall, E, Kebriaei, P. Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Advances 8(5):1128-1136, 2024. e-Pub 2024. PMID: 38266155.
22. Nieto, Y, Yang, Z, Valdez, B, Kundu, S, Bashir, Q, Ramdial, JL, Srour, S, Qazilbash, MH. Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma. American journal of hematology 99(2):245-253, 2024. e-Pub 2024. PMID: 38100199.
23. Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, Srour S, Mehta R, Alousi A, Popat UR, Nieto Y, Kebriaei P, Al-Atrash G, Oran B, Hosing C, Ahmed S, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation. Transplantation and Cellular Therapy 30(2):205.e1-205.e12, 2024. e-Pub 2023. PMID: 37437764.
24. Pasvolsky, O, Ghanem, S, Milton, D, Masood, A, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplantation and Cellular Therapy 29(12):757-762, 2023. e-Pub 2023. PMID: 37673125.
25. Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MH. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood cancer journal 13(1), 2023. e-Pub 2023. PMID: 37137874.
26. Joseph, JJ, Srour, S, Milton, D, Ramdial, JL, Saini, N, Olson, AL, Bashir, Q, Oran, B, Alousi, AM, Hosing, C, Qazilbash, MH, Kebriaei, P, Shpall, E, Champlin, RE, Popat, UR. Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplantation and Cellular Therapy 29(12):770.e1-770.e6, 2023. e-Pub 2023. PMID: 37742746.
27. Popat, UR, Pasvolsky, O, Bassett Jr, R, Mehta, RS, Olson, AL, Chen, J, Alousi, AM, Al-Atrash, G, Bashir, Q, Gulbis, A, Hosing, C, Im, JS, Kebriaei, P, Khouri, IF, Marin, D, Nieto, Y, Oran, B, Saini, N, Shigle, TL, Srour, S, Ramdial, JL, Rezvani, K, Qazilbash, MH, Andersson, BS, Champlin, RE, Shpall, E. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Advances 7(20):6196-6205, 2023. e-Pub 2023. PMID: 37611156.
28. Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma. American journal of hematology 98(10):1571-1578, 2023. e-Pub 2023. PMID: 37461327.
29. Al-Juhaishi T, Wang Y, Milton DR, Xu-Monette ZY, Jabbour E, Daher M, Im JS, Bashir Q, Iyer SP, Marin D, Olson AL, Popat U, Qazilbash M, Rondon G, Gulbis AM, Champlin RE, Young KH, Khouri IF. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone marrow transplantation 58(9):1000-1007, 2023. e-Pub 2023. PMID: 37198234.
30. Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. British Journal of Haematology 202(4):866-873, 2023. e-Pub 2023. PMID: 37376789.
31. Bashir Q, Nishihori T, Pasquini MC, Martens MJ, Wu J, Alsina M, Anasetti C, Brunstein C, Dawson P, Efebera Y, Gasparetto C, Geller N, Giralt S, Hall AC, Koreth J, McCarthy P, Scott E, Stadtmauer EA, Vesole DH, Hari P. A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma. Transplantation and Cellular Therapy 29(6):358.e1-358.e7, 2023. e-Pub 2023. PMID: 35840087.
32. Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14). Transplantation and Cellular Therapy 29(4):260.e1-260.e6, 2023. e-Pub 2023. PMID: 36646323.
33. Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplantation and Cellular Therapy 29(4):264.e1-264.e9, 2023. e-Pub 2023. PMID: 35605883.
34. Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ. HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection. Transplantation and Cellular Therapy 29(3):189-198, 2023. e-Pub 2023. PMID: 36470579.
35. Damron, EP, Qazilbash, MH, Fang, PQ, Wu, SY, Dabaja, BS, Rondon, G, Hosing, C, Champlin, RE, Bashir, Q, Shpall, E, Knafl, M, Lee, HC, Manasanch, EE, Patel, K, Thomas, SK, Orlowski, R, Weber, DM, Pinnix, CC, Gunther, J. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplantation and Cellular Therapy 29(1):37.e1-37.e7, 2023. e-Pub 2023. PMID: 37753818.
36. Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplantation and Cellular Therapy 28(11):752.e1-752.e6, 2022. e-Pub 2022. PMID: 35940528.
37. Pasvolsky, O, Milton, D, Rauf, M, Ghanem, S, Masood, A, Mohamedi, A, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Lin, P, Qazilbash, MH. MM-403 Impact of Clonal Plasma Cells in Autografts on the Outcome of High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia 22:S421-S422, 2022. e-Pub 2022. PMID: 36164172.
38. Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan?±?clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant 57(8):1295-1303, 2022. e-Pub 2022. PMID: 35610308.
39. Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors?. Transplant Cell Ther 28(8):500.e1-500.e10, 2022. e-Pub 2022. PMID: 35662592.
40. Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Post-Transplantation Cyclophosphamide vs Tacrolimus and Methotrexate Graft-versus-Host Disease Prophylaxis For HLA-Matched Donor Transplantation. Transplant Cell Ther. e-Pub 2022. PMID: 35902049.
41. Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant. e-Pub 2022. PMID: 35523847.
42. Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical vs Matched Unrelated vs Matched Sibling Donor HCT with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. e-Pub 2022. PMID: 35513252.
43. Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction with VCD vs. VRD on the Outcome of Patients with Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. e-Pub 2022. PMID: 35331973.
44. Qazilbash MH, Saini NY, Cha SC, Wang Z, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, Kim K, Popescu M, Szymura S, Zhang T, Anderson A, Bashir Q, Shpall EJ, Orlowski RZ, Levine BL, Kerr N, Garfall A, Cohen A, Vogl DT, Dengel K, June CH, Champlin R, Kwak LW. A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients. Blood 139(9):1289-1301, 2022. e-Pub 2022. PMID: 34521108.
45. Kawedia JD, Ramchandran S, Liu X, Gulbis AM, Titus M, Bashir Q, Qazilbash MH, Champlin RE, Ciurea SO. Stability of Captisol-enabled versus propylene glycol-based melphalan at room temperature and after refrigeration. Am J Health Syst Pharm. e-Pub 2022. PMID: 35176751.
46. Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, Chen Y, Boumendil A, Zain J, Castagna L, Cashen AF, Blaise D, Shadman M, Pastano R, Khimani F, Arat M, Dietrich S, Schmitz N, Glass B, Kharfan-Dabaja MA, Corradini P, Sauter CS, Montoto S, Kwon M, Herrera AF, Dreger P. Outcome of Allogeneic Transplantation for Mature T-cell Lymphomas: Impact of Donor Source and Disease Characteristics. Blood Adv 6(3):920-930, 2022. e-Pub 2022. PMID: 34861680.
47. Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EE, Olsem J, Morphey A, Huo XJ, Thomas SK, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-transplant Myeloma Patients. Clin Cancer Res. e-Pub 2022. PMID: 34992070.
48. Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96(12):E455-E457, 2021. e-Pub 2021. PMID: 34559916.
49. Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106(12):3211-3214, 2021. e-Pub 2021. PMID: 34407606.
50. Khouri IF, Milton DR, Gulbis AM, Jabbour EJ, Nastoupil L, Ledesma C, Anderlini P, Bashir Q, Daher M, Im JS, Iyer SP, Marin D, Mehta RS, Olson AL, Popat UR, Qazilbash M, Saini N, Samaniego F, Rondon G, Medeiros LJ, Champlin RE. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clin Cancer Res 27(21):5847-5856, 2021. e-Pub 2021. PMID: 34380640.
51. Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant. e-Pub 2021. PMID: 34629467.
52. Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma:1-12. e-Pub 2021. PMID: 34686083.
53. Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, Bayer RL, Coleman M, DeFilipp Z, Farhadfar N, Greenwood M, Hahn T, Horwitz M, Jacobson C, Jaglowski S, Lachance S, Langston A, Mattar B, Maziarz RT, McGuirk J, Mian MAH, Nathan S, Phillips A, Rakszawski K, Sengeloev H, Shenoy S, Stuart R, Sauter CS, Kharfan-Dabaja MA, Hamadani M. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv 5(18):3528-3539, 2021. e-Pub 2021. PMID: 34496026.
54. Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. e-Pub 2021. PMID: 34537419.
55. Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica 106(7):1988-1990, 2021. e-Pub 2021. PMID: 31296578.
56. Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. e-Pub 2021. PMID: 34312462.
57. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther. e-Pub 2021. PMID: 34329753.
58. Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, Alousi AM, Andersson BS, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin R, Popat U. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther 27(5):430.e1-430.e7, 2021. e-Pub 2021. PMID: 33965187.
59. Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther 27(5):404.e1-404.e5, 2021. e-Pub 2021. PMID: 33965178.
60. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol 193(3):e23-e26, 2021. e-Pub 2021. PMID: 33748943.
61. Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat U. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplant. e-Pub 2021. PMID: 33846563.
62. Shah MV, Saliba RM, Verma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol. e-Pub 2021. PMID: 33821472.
63. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol:JCO2002608. e-Pub 2021. PMID: 33929874.
64. Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther 27(3):243.e1-243.e6, 2021. e-Pub 2021. PMID: 33781521.
65. Manasanch EE, Berrios D, Fountain E, Claussen CM, Chuang T, Kaufman G, Amini B, Bashir Q, Nieto Y, Qazilbash M, Patel K, Thomas SK, Weber DM, Berkova Z, Toruner G, Lin P, Feng L, Lee HC, Orlowski RZ, Kunacheewa C. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol 192(4):e115-e120, 2021. e-Pub 2021. PMID: 33486754.
66. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta haematologica 144(1):74-81, 2021. e-Pub 2021. PMID: 32604096.
67. Oran B, Saliba RM, Mehta RS, Alousi AM, Marin D, Valdez BC, Chen J, Bashir Q, Ciurea SO, Olson AL, Hosing C, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Andersson BS, Popat UR. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. e-Pub 2021. PMID: 33471943.
68. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia 34(12):3338-3347, 2020. e-Pub 2020. PMID: 32313109.
69. Bashir Q, Acosta M. Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions. Clinical Lymphoma, Myeloma and Leukemia 20(11):768-773, 2020. e-Pub 2020. PMID: 32900662.
70. Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei P. Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia. Blood 136(15):1786-1789, 2020. e-Pub 2020. PMID: 32492706.
71. Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances 4(13):3180-3190, 2020. e-Pub 2020. PMID: 32663298.
72. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 26(6):1077-1083, 2020. e-Pub 2020. PMID: 31786242.
73. Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K, Popat UR, Shpall EJ, Champlin RE, Oran B. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer 126(10):2183-2192, 2020. e-Pub 2020. PMID: 32101640.
74. Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia 20(5):e221-e238, 2020. e-Pub 2020. PMID: 32037287.
75. Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation. Blood Advances 4(7):1296-1306, 2020. e-Pub 2020. PMID: 32236526.
76. Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
77. Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin RE. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?. Blood 135(6):449-452, 2020. e-Pub 2020. PMID: 31826244.
78. Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Bashir Q, Qazilbash MH, Andersson BS. Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells. Experimental Hematology 81:32-41, 2020. e-Pub 2020. PMID: 31954171.
79. Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash M, Mehta R, Shpall EJ, Alousi A, Khouri I, Kebriaei P, Popat U, Champlin RR, Ciurea SO. Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 26(1):197-203, 2020. e-Pub 2020. PMID: 31518645.
80. Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years. Leukemia and Lymphoma 60(14):3536-3543, 2019. e-Pub 2019. PMID: 31282244.
81. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. American journal of hematology 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
82. Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of autologous transplantation in patients with multiple myeloma with t(11;14). Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
83. Ciurea SO, Varma A, Kongtim P, Srour S, Bashir Q, Alousi AM, Mehta RS, Oran B, Popat U, Hosing C, Rondon G, Chen J, Olson AL, Konopleva MY, Champlin RE. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Blood 134(1), 2019. e-Pub 2019. PMID: 31724003.
84. Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clinical Lymphoma, Myeloma and Leukemia 19(9):560-569, 2019. e-Pub 2019. PMID: 31201134.
85. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biology of Blood and Marrow Transplantation 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
86. Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies. Biology of Blood and Marrow Transplantation 25(7):1347-1354, 2019. e-Pub 2019. PMID: 30826465.
87. Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia. Bone marrow transplantation 54(7):1089-1093, 2019. e-Pub 2019. PMID: 30446740.
88. Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone marrow transplantation 54(6):839-848, 2019. e-Pub 2019. PMID: 30258129.
89. Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Bashir Q. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Current Research in Translational Medicine 67(2):51-55, 2019. e-Pub 2019. PMID: 30683577.
90. Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MH. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biology of Blood and Marrow Transplantation 25(5):1039-1044, 2019. e-Pub 2019. PMID: 30639822.
91. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma. The Lancet Haematology 6(5):e266-e275, 2019. e-Pub 2019. PMID: 30910541.
92. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica. e-Pub 2019. PMID: 30948491.
93. Sahebi F, Garderet L, Kanate AS, Eikema DJ, Knelange NS, Alvelo OFD, Koc Y, Blaise D, Bashir Q, Moraleda JM, Dreger P, Sanchez JF, Ciurea S, Schouten H, Shah NN, Verbeek M, Rösler W, Diez-Martin JL, Schoenland S, D'Souza A, Kröger N, Hari P. Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation 25(2):335-342, 2019. e-Pub 2019. PMID: 30243581.
94. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma 60(2):1-11, 2019. e-Pub 2019. PMID: 30032678.
95. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol 94(1):E2-E5, 2019. e-Pub 2019. PMID: 30300461.
96. Khan MA, Bashir Q, Chaudhry QU, Ahmed P, Satti TM, Mahmood SK. Review of Haploidentical Hematopoietic Cell Transplantation. J Glob Oncol 4(4):1-13, 2018. e-Pub 2018. PMID: 30521413.
97. Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol 5(11):e532-e542, 2018. e-Pub 2018. PMID: 30389035.
98. Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24(11):2197-2203, 2018. e-Pub 2018. PMID: 30016656.
99. Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, Popat U, Bashir Q, Oran B, Hosing CM, Khouri IF, Kebriaei P, Champlin RE. Is a matched unrelated donor search needed for all allogeneic transplant candidates?. Blood Adv 2(17):2254-2261, 2018. e-Pub 2018. PMID: 30206098.
100. Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. Br J Haematol 182(6):916-920, 2018. e-Pub 2018. PMID: 28771676.
101. Malek E, Gupta V, Creger R, Caimi P, Vatsayan A, Covut F, Bashir Q, Champlin R, Delgado R, Rondon G, Cooper B, de Lima M, Lazarus HM, Qazilbash M. Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. Leuk Lymphoma 59(8):1-8, 2018. e-Pub 2018. PMID: 29295650.
102. Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant 24(7):1514-1520, 2018. e-Pub 2018. PMID: 29448058.
103. Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Perez JMR, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin RE. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood 131(26):2989-2992, 2018. e-Pub 2018. PMID: 29769261.
104. Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, Daver N, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin RE. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 24(6):1232-1236, 2018. e-Pub 2018. PMID: 28918304.
105. Shah N, Shi Q, Giralt S, Williams L, Bashir Q, Qazilbash M, Champlin RE, Cleeland CS, Wang XS. Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. Qual Life Res 27(4):979-985, 2018. e-Pub 2018. PMID: 29260444.
106. Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood 131(11):1248-1257, 2018. e-Pub 2018. PMID: 29386198.
107. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma 59(2):1-4, 2018. e-Pub 2018. PMID: 28673185.
108. Shah N, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, Parmar S, Hosing C, Popat U, Shpall EJ, Champlin RE, Qazilbash M. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. European Journal of Haematology 99(6):532-535, 2017. e-Pub 2017. PMID: 28895206.
109. Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol 179(5):781-789, 2017. e-Pub 2017. PMID: 28980314.
110. Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer 123(18):3568-3575, 2017. e-Pub 2017. PMID: 28513828.
111. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat U, Khouri I, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. Cancer 123(14):2661-2670, 2017. e-Pub 2017. PMID: 28324640.
112. Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma. The Lancet Haematology 4(6):e283-e292, 2017. e-Pub 2017. PMID: 28522110.
113. Pak JH, Bashir Q, Kim IK, Hong SJ, Maeng S, Bahk YY, Kim TS. Clonorchis sinensis excretory-secretory products promote the migration and invasion of cholangiocarcinoma cells by activating the integrin β4-FAK/Src signaling pathway. Mol Biochem Parasitol 214:1-9, 2017. e-Pub 2017. PMID: 28286026.
114. Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. British Journal of Haematology 177(3):457-466, 2017. e-Pub 2017. PMID: 28295190.
115. Aziz I, Rashid N, Ashraf R, Bashir Q, Imanaka T, Akhtar M. Pcal_0111, a highly thermostable bifunctional fructose-1,6-bisphosphate aldolase/phosphatase from Pyrobaculum calidifontis. Extremophiles 21(3):513-521, 2017. e-Pub 2017. PMID: 28299451.
116. Ge I, Saliba RM, Maadani F, Popat UR, Qazilbash MH, Ravi Pingali S, Shah N, Ahmed S, Bashir Q, Nieto Y, Champlin RE, Hosing C. Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. Transfusion 57(4):1052-1057, 2017. e-Pub 2017. PMID: 28185276.
117. Varma A, Biritxinaga L, Saliba RM, Stich M, Jauch SF, Afrough A, Honhar M, Popat UR, Shafi MA, Shah N, Bashir Q, Dinh Y, Hosing C, Champlin RE, Qazilbash MH. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation 23(4):581-587, 2017. e-Pub 2017. PMID: 28063964.
118. Badar T, Srour S, Bashir Q, Shah N, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. European Journal of Haematology 98(3):263-268, 2017. e-Pub 2017. PMID: 27862330.
119. Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation 23(2):269-277, 2017. e-Pub 2017. PMID: 27864161.
120. Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation 23(2):285-292, 2017. e-Pub 2017. PMID: 27816651.
121. Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Bassett R, Lyons G, Chen J, Rezvani K, Popat U, Kebriaei P, Patel K, Rondon G, Shpall EJ, Champlin RE. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica 102(1):110-117, 2017. e-Pub 2017. PMID: 27540139.
122. Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer 122(24):3831-3837, 2016. e-Pub 2016. PMID: 27680710.
123. Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 22(12):2159-2164, 2016. e-Pub 2016. PMID: 27638366.
124. Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 122(21):3316-3326, 2016. e-Pub 2016. PMID: 27404668.
125. Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. European Journal of Haematology 97(4):342-347, 2016. e-Pub 2016. PMID: 26773409.
126. Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MH. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. American journal of hematology 91(10):E442-E447, 2016. e-Pub 2016. PMID: 27420405.
127. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer 122(17):2680-2688, 2016. e-Pub 2016. PMID: 27203405.
128. Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. British Journal of Haematology 174(2):235-248, 2016. e-Pub 2016. PMID: 26989808.
129. Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A, Qazilbash M, Bashir Q, Ahmed S, Popat U, Hosing C, Khouri I, Shpall EJ, Champlin RE, Ciurea SO. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. British Journal of Haematology 173(3):444-455, 2016. e-Pub 2016. PMID: 26947769.
130. Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat U. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biology of Blood and Marrow Transplantation 22(5):961-965, 2016. e-Pub 2016. PMID: 26921820.
131. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia 16(3):122-128, 2016. e-Pub 2016. PMID: 26795083.
132. Shah N, Shi Q, Williams LA, Mendoza TR, Wang XS, Reuben JM, Dougherty PM, Bashir Q, Qazilbash MH, Champlin RE, Cleeland CS, Giralt SA. Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biology of Blood and Marrow Transplantation 22(2):226-231, 2016. e-Pub 2016. PMID: 26253006.
133. Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Nonsecretory Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia 16(1):36-42, 2016. e-Pub 2016. PMID: 26702475.
134. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation 21(11):1914-1920, 2015. e-Pub 2015. PMID: 26071868.
135. Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir Q. Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation. Clinical Lymphoma, Myeloma and Leukemia 15(11):687-693, 2015. e-Pub 2015. PMID: 26361647.
136. Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson B, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes. Biology of Blood and Marrow Transplantation 21(8):1405-1412, 2015. e-Pub 2015. PMID: 25840338.
137. Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MH. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, andSoft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 21(8):1413-1417, 2015. e-Pub 2015. PMID: 25842049.
138. El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia 15(8):472-476, 2015. e-Pub 2015. PMID: 25963284.
139. Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar S. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone marrow transplantation 50(5):668-672, 2015. e-Pub 2015. PMID: 25730192.
140. Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson BS, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-2892, 2015. e-Pub 2015. PMID: 25778529.
141. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 2015. e-Pub 2015. PMID: 25778529.
142. Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, Shah J, Orlowski RZ, Qazilbash MH. Chromosome 8q24.1/c-MYC abnormality. Leukemia and Lymphoma 56(3):602-607, 2015. e-Pub 2015. PMID: 24844357.
143. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biology of Blood and Marrow Transplantation 20(12):1975-1981, 2014. e-Pub 2014. PMID: 25263628.
144. Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, Shah N, Popat U, Giralt SA, Orlowski RZ, Qazilbash MH. Auto-SCT improves survival in systemic light chain amyloidosis. Bone marrow transplantation 49(8):1036-1041, 2014. e-Pub 2014. PMID: 24887378.
145. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biology of Blood and Marrow Transplantation 19(10):1453-1458, 2013. e-Pub 2013. PMID: 23872222.
146. Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. Biology of Blood and Marrow Transplantation 19(8):1227-1232, 2013. e-Pub 2013. PMID: 23733001.
147. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-417, 2013. e-Pub 2013. PMID: 23128322.
148. Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO. Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 19(3):344-356, 2013. e-Pub 2013. PMID: 22922522.
149. Aung F, Lichtiger B, Bassett R, Liu P, Alousi A, Bashir Q, Ciurea S, de Lima M, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin R, Popat U. Incidence and Natural History of Pure Red Cell Aplasia in Major ABO-mismatched Haematopoietic Cell Transplantation. British Journal of Haematology 160(6):798-805, 2013. e-Pub 2013.
150. Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-20, 2013. e-Pub 2013. PMID: 22982533.
151. Bashir Q, William BM, Garcia-Manero G, de Lima M. Epigenetic therapy in allogeneic hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter 35(2):126-33, 2013. e-Pub 2013. PMID: 23741191.
152. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(12):1835-44, 2012. e-Pub 2012. PMID: 22796535.
153. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autolgous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies. Biol Blood Marrow Transplant 18(11):1677-86, 2012. e-Pub 2012. PMID: 22643322.
154. Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leukemia and Lymphoma 53(8):1525-1529, 2012. e-Pub 2012. PMID: 22242817.
155. Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, Wen S, Thall P, Khan H, Giralt S, Champlin R, Qazilbash MH. Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma. Cancer 118(14):3549-55, 2012. e-Pub 2012. PMID: 22086552.
156. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(26):6373-8, 2012. e-Pub 2012. PMID: 22586182.
157. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-15, 2012. e-Pub 2012. PMID: 21887685.
158. Bashir Q, Munsell MF, Giralt S, de Padua Silva L, Sharma M, Couriel D, Chiattone A, Popat U, Qazilbash MH, Fernandez-Vina M, Champlin RE, de Lima MJ. Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. Leuk Lymphoma 53(5):915-919, 2012. e-Pub 2012. PMID: 22023525.
159. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-276, 2012. e-Pub 2012. PMID: 22231283.
160. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplant in patients aged greater than 70 years with multiple myeloma. Leukemia and Lymphoma 53(1):118-22, 2012. e-Pub 2012. PMID: 21780997.
161. Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M. Treatment of FLT3-ITD Positive Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation with Sorafenib. Biol Blood Marrow Transplant 17(12):1874-7, 2011. e-Pub 2011. PMID: 21767516.
162. Bashir Q, Andersson BS, Fernandez-Vina M, de Padua Silva L, Giralt S, Chiattone A, Wei W, Sharma M, Anderlini P, Shpall EJ, Popat U, Rodrigues M, Champlin RE, de Lima M. Unrelated Donor Transplantation for Acute Myelogenous Leukemia in First Remission. Biol Blood Marrow Transplant 17(7):1067-71, 2011. e-Pub 2011. PMID: 21087679.
163. Bashir Q, Langford LA, Parmar S, Champlin RE, Qazilbash MH. Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection. J Clin Oncol 29(4):e79-e80, 2011. e-Pub 2011. PMID: 21060030.
164. Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leukemia and Lymphoma 51(8):1478-1484, 2010. e-Pub 2010. PMID: 20658954.
165. Bashir Q, Lee CK, Stuart RW, Smith ML, Ryder J, Gonzalez R. Phenotypic evolution of Waldenstrom's macroglobulinemia to extramedullary plasmacytoma. Journal of Clinical Oncology 26(14):2408-2410, 2008. e-Pub 2008. PMID: 18467735.
166. Badar T, Hari P, Dávila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer 127(1):82-92. PMID: 32966625.

Invited Articles

1. AM Trottier AM, S Bannon S, Q Bashir Q, HE Carraway HE, I Hofmann I, LA Godley LA. When should transplant physicians think about familial blood cancers?. Adv Cell Gene Ther. e-Pub 2019.
2. Bashir Q, Robinson SN, de Lima MJ, Parmar S, Shpall E. Umbilical Cord Blood Transplantation. Clinical Advances in Hematology and Oncology 8(11):786-801, 2010. e-Pub 2010. PMID: 21326157.

Review Articles

1. Aslam, MF, Cheema, AY, Shahid, D, Maryam, B, Mukhopadhyay, D, Munir, M, Najam, A, Ali, HM, Bashir, Q, Anwer, F. Historical Perspective of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Acta haematologica 148(3):315-329, 2025. e-Pub 2025. PMID: 39586285.
2. Bashir, Q, Braunstein, M, Buck, T, Chmielewski, C, Hartmann, B, Janakiram, M, McMahon, MA, Romundstad, L, Steele, L, Usmani, S, Zwibel, K, Kharfan-Dabaja, MA. Overcoming Barriers to Autologous Stem Cell Transplantation in Multiple Myeloma. Transplantation and Cellular Therapy 29(11):666-673, 2023. e-Pub 2023. PMID: 37661071.
3. Greenbaum U, Kebriaei P, Srour SA, Olson A, Bashir Q, Neelapu SS, Rezvani K, Shpall EJ. Chimeric Antigen Receptor T-cell Therapy Toxicities. Br J Clin Pharmacol. e-Pub 2020. PMID: 32463929.
4. Chaudhri NA, Aljurf M, Almohareb FI, Alzahrani HA, Bashir Q, Savani B, Gupta V, Hashmi SK. Establishing an autologous versus allogeneic hematopoietic cell transplant program in nations with emerging economies. Hematology/ Oncology and Stem Cell Therapy 10(4):173-177, 2017. e-Pub 2017. PMID: 28692818.
5. Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood 129(22):3031-3033, 2017. e-Pub 2017. PMID: 28351938.
6. Bashir Q, Qazilbash MH. Allogeneic Hematopoietic Cell Transplantation for Myeloma. Current hematologic malignancy reports 12(2):126-135, 2017. e-Pub 2017. PMID: 28285435.
7. Govindarajan G, Bashir Q, Kuppuswamy S, Brooks C. Sweet syndrome associated with furosemide. Southern Medical Journal 98(5):570-572, 2005. e-Pub 2005. PMID: 15954518.
8. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. Journal of Clinical Oncology 23(30):7685-7696, 2005. e-Pub 2005. PMID: 16234530.

Other Articles

1. Pasvolsky O, Bashir Q Autologous transplant and second malignancies in MM. Blood Advances 7(12):2731-2732, 2023. PMID: 37318936.
2. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia 35(7):2141, 2021. PMID: 34091601.
3. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A Correction to. Leukemia 35(6):1828, 2021. PMID: 33782538.
4. Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Advances 4(19):4834-4837, 2020. PMID: 33027527.
5. Shigle TL, Bashir Q Advancement in monoclonal antibody therapy for multiple myeloma. The Lancet Haematology 7(5):e354-e355, 2020. PMID: 32213343.
6. Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clinical Lymphoma, Myeloma and Leukemia 14(1):e1-e5, 2014. PMID: 24169268.

Abstracts

1. Sarubbi C, Miatech J, Forsberg MA, Demla AE, Rahman Z, Pawelek J, Mitchell D, Donald S, Garcia C, Suello K, Codrington K, Hunter L, Garcia R, Martinez CS, Rondon G, Al-Atrash G, Aljawai YM, Alousi AM, Bashir Q, Champlin RE, Chen GL, Hosing C, Im JS, Kebriaei P, Khouri IF, Lin P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Popat UR, Smallbone P, Srour SA, Tewari P, Flowers CR, Shpall EJ, Fingrut WB. Optimizing Essential, Complex Hematologic Care for Patients Living with Disabilities. ASTCT Tandem 2026, 2026. e-Pub 2026.
2. Popat UR, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Champlin RE, Shpall EJ. Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa, and Venetoclax (Cladillac) Conditioning for High-Risk AML: A Phase 2 Trial. ASTCT Tandem 2026, 2026. e-Pub 2026.
3. Popat UR, Hosing C, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Bazinet A, Garcia-Manero G, Champlin RE. A Phase 2 Trial of Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa, and Venetoclax (Cladillac) Conditioning for High-Risk MDS. ASTCT Tandem 2026, 2026. e-Pub 2026.
4. Kawedia JD, Anderson T, Liu X, Gulbis AM, Qazilbash MH, Bashir Q. Evaluation of Melphalan Population Pharmacokinetic Models to Predict Propylene Glycol-Free Melphalan (Evomela) Clearance. ASTCT Tandem 2026, 2026. e-Pub 2026.
5. Miatech J, Mehta RS, Ramdial JL, Rondon G, Alatrash G, Aljawai YM, Alousi AM, Bashir Q, Chen GL, Hosing C, Fingrut WB, Kebriaei P, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Popat UR, Qazilbash MH, Smallbone P, Srour SA, Tanner MR, Rezvani K, Champlin RE, Shpall EJ, Saliba RM. MMF Use Is Associated with Increased Early Infections in AML/MDS Patients Undergoing Allogeneic Transplant with PTCy-Based GvHD Prophylaxis. ASTCT Tandem 2026, 2026. e-Pub 2026.
6. Forsberg MA, Pirtle R, Daher M, Kaur I, Shaftoe S, Castro Miranda KM, Popat UR, Washington D, Asfaw T, Ramirez A, Mulanovich VE, Nieto Y, Basar R, Fingrut WB, Lin P, Oran B, Alousi AM, Kebriaei P, Srour SA, Ramdial JL, Saini NY, Chen GL, Im JS, Aljawai YM, Khouri IF, Olson AL, Mehta RS, Bashir Q, Champlin RE, Shpall EJ, Rezvani K, Marin D. Administration of Off-the-Shelf, Expanded, Most Closely HLA Matched, Third Party Viral Specific T cells for the Therapy of Adenovirus Related Disease in Adult Immunocompromised Patients. ASTCT Tandem 2026, 2026. e-Pub 2026.
7. Pasvolsky O, Abid MB, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial JL, Nieto Y, Tang G, Haider AA, Aljawai YM, Kebriaei P, Gaballa M, Patel KK, Ye C, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone, Upfront Autologous Transplant and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma. ASTCT Tandem 2026, 2026. e-Pub 2026.
8. Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial JL, Nieto Y, Tang G, Haider AA, Goklemez S, Aljawai YM, Kebriaei P, Patel KK, Gaballa M, Ye C, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Peripheral Blood Stem Cell Collection for Patients with Multiple Myeloma Undergoing Autologous Transplant after Quadruplet Induction. ASTCT Tandem 2026, 2026. e-Pub 2026.
9. Rafique AJ, Faisal A, Bashir Q, Saini NY, Aljawai YM, Hosing C, Popat UR, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Srou SA. Impact of Renal Function on Autologous Stem Cell Transplantation (ASCT) Outcomes for AL Amyloidosis. ASTCT Tandem 2026, 2026. e-Pub 2026.
10. Bashir Q, Thall PF, Xu X, Kawedia JD, Knape C, Delgado R, Popat UR, Hosing C, Aljawai YM, Chen GL, Fingrut WB, Im JS, Kebriaei P, Marin D, Nieto Y, Ahmed S, Olson AL, Oran B, Ramdial JL, Saini NY, Smallbone P, Srour SA, Pasvolsky O, Thomas SK, Ye C, Patel KK, Champlin RE, Shpall EJ, Qazilbas MH. Evaluate the Safety and Efficacy of Short Versus Long Infusion Schedules of Evomela As Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma.Interpret Bayesian Modeling Results Assessing the Relationship between Melphalan Exposure (AUC) and Depth of Response or Progression-Free Survival.Identify Potential Pharmacokinetic (AUC) Targets That May Guide Individualized Evomela Dosing Strategies, Particularly for Patients with High-Risk Cytogenetics. ASTCT Tandem 2026, 2026. e-Pub 2026.
11. Miatech J, Mehta RS, Ramdial JL, Rondon G, Alatrash G, Aljawai YM, Alousi AM, Bashir Q, Chen GL, Hosing C, Fingrut WB, Kebriaei P, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Popat UR, Qazilbash MH, Smallbone P, Srour SA, Tanner MR, Rezvani K, Champlin RE, Shpall EJ, Saliba RM. Adverse Impact of MMF in AML/MDS Patients with High HCT-CI Receiving Matched Allogeneic Stem Cell Transplantation with PTCy-Based GvHD Prophylaxis. ASTCT Tandem 2026, 2026. e-Pub 2026.
12. Sarubbi C, Miatech J, Forsberg M, Demla A, Rahman Z, Pawelek J, Mitchell D, Donald S, Garcia C, Suello K, Codrington K, Hunter L, Garcia R, Martinez C, Rondon G, Alatrash G, Aljawai Y, Alousi A, Bashir Q, Champlin R, Fingrut W. Optimizing essential, complex hematologic care for patients living with disabilities. ASH 2025, 2025. e-Pub 2025.
13. Saliba RM, Miatech J, Ramdial J, Rondon G, Alatrash G, Alousi A, Bashir Q, Chen G, Fingrut W, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat U, Qazilbash M, Smallbone P, Srour S, Meht R. MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis. ASH 2025, 2025. e-Pub 2025.
14. Popat U, Bassett R, Alousi A, Alatrash G, Aljawai Y, Bashir Q, Chen G, Fingrut W, Hosing C, Im J, Kebriaei P, Marin D, Nieto Y, Olson A, Oran B, Qazilbash M, Ramdial J, Saini N, Smallbone P, Srour S, Shpall E. Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial. ASH 2025, 2025. e-Pub 2025.
15. Pleitez HG, Pasvolsky O, Feng L, Gaballa M, Hunzeker Z, Thomas S, Weber D, Kalariya N, Chen J, Abreu M, Varghese J, Hawkins M, Dillard C, Becnel M, Saini N, Qazilbash M, Bashir Q, Thakral B, Ye J, Kaufman G, Orlowski R, Wang S, Patel K. BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma. ASH 2025, 2025. e-Pub 2025.
16. Pasvolsky O, Abid MB, Milton D, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Haider A, Aljawai Y, Kebriaei P, Gaballa M, Patel K, Ye JC, Thomas S, Orlowski R, Champlin R, Qazilbash M. Daratumumab, bortezomib, lenalidomide and dexamethasone, upfront autologous transplant and lenalidomide maintenance for newly diagnosed multiple myeloma. ASH 2025, 2025. e-Pub 2025.
17. Hosing C, Saliba RM, Alousi A, Alatrash G, Aljawai Y, Bashir Q, Chen G, Fingrut W, Im J, Kebriaei P, Marin D, Nieto Y, Olson A, Oran B, Qazilbash M, Ramdial J, Smallbone P, Popat U, Champlin R, Maadani F, Srour S. Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis. ASH 2025, 2025. e-Pub 2025.
18. Forsberg M, Kaur I, Pirtle R, Daher M, Basar R, Washington D, Asfaw T, Castro K, Ramirez A, Shaftoe S, Oran B, Lin P, Nieto Y, Mulanovich V, Ariza-Heredia E, Aljawai Y, Chen G, Alousi A, Kebriaei P, Fingrut W, Marin D. Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients. ASH 2025, 2025. e-Pub 2025.
19. Pasvolsky O, Milton D, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Haider A, Goklemez S, Aljawai Y, Kebriaei P, Patel K, Gaballa M, Ye JC, Thomas S, Orlowski R, Champlin R, Qazilbash M. Peripheral blood stem cell collection for patients with multiple myeloma undergoing autologous transplant after quadruplet induction. ASH 2025, 2025. e-Pub 2025.
20. Wakefield C, Milton D, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Haider A, Aljawai Y, Kebriaei P, Patel K, Thomas S, Orlowski R, Champlin R, Shpall E, Qazilbash M, Pasvolsky O. Simplified frailty score for patients with multiple myeloma undergoing autologous stem cell transplant. ASH 2025, 2025. e-Pub 2025.
21. Popat U, Bassett R, Thall P, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im J, Kebriaei P, Marin D, Mehta R, Nieto Y, Olson A, Oran B, Ramdial JL, Saini N, Srour S, Valdez B, Qazilbash MH, Kawedia J, Daver N, Ravandi-Kashani F, EChamplin R, Shpall EJ, Andersson B. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib for Allogeneic Stem Cell Transplant in Patients with AML: Results of a Phase 1/2 Clinical Trial. European Hematology Association (EHA) Congress 2025, 2025. e-Pub 2025.
22. Popat -U, Bassett Jr -R, Thall P, Alousi A, Alatrash G, Bashir Q, Hosing C, Seon Im J, Kebriaei P, Marin D, Mehta R, Nieto Y, Olson A, Oran B, Valdez B, Qazilbash M, Champlin R, Shpall E, Andersson B. Myeloablative fractionated busulfan conditioning regimen with sorafenib for allogeneic stem cell transplant in AML: Results of a phase 1/2 study. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
23. Haider AA, Milton DR, Tanner MR, Bashir Q, Smallbone P, Srour S, Saini N, Lin P, Ramdial JL, Nieto Y, Tang G, Mohamedi AH, Aljawai Y, Kebriaei P, Lee H, Patel KK, Becnel MR, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O. Lenalidomide Maintenance After Delayed or Salvage Autologous Stem Cell Transplantation, 2025. e-Pub 2025.
24. Srour S, Bashir Q, Saini N, Aljawai Y, Hosing C, Popat U, Becnel MR, Kaufman G, Thomas SK, Weber D, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbas MH. Impact of Free Light Chains Burden On Autologous Stem Cell Transplantation (ASCT) Outcomes for AL Amyloidosis. EHA 2025, 2025. e-Pub 2025.
25. Aljawai Y, Saini N, Milton DR, Popat U, Kebriaei P, Hosing C, Al‑Atrash G, Srour S, Lee H, Pasvolsky O, Patel K, Thomas SK, Orlowski RZ, Gaballa M, Ye JC, Kim R, Lin P, Patel N, Razmandi A, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Interim Analysis of MRD‑Guided Maintenance Therapy with Belantamab, Mafodotin and Lenalidomide After Auto‑Hct in Newly Diagnosed Multiple Myeloma. EHA 2025, 2025. e-Pub 2025.
26. Cervoni-Curet FN, Milton DR, Garcia R, Hunter L, Ledesma C, Martinez CS, Rondon G, Carmazzi Y, Cao K, Al-Atrash G, Aljawai YM, Alousi AM, Bashir Q, Chen GL, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Smallbone P, Saini NY, Srour SA, Champlin RE, Flowers C, Shpall EJ. Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide (PTCy)-Based Graft-Versus-Host Disease Prophylaxis. TANDEM Meetings of ASTCT and CIBMTR 2025, 2025. e-Pub 2025.
27. Aljawai Y, Bashir Q, Rezvani K, Qazilbash M, Chen G, Champlin R, Marin D, Alousi A, Ramdial J, Oran B, Shpall E, Fingrut W, Kebriaei P, Mehta R, Popat U, Hosing C. Impact of Donor Age and Donor-Recipient Sex Mismatch on Hematopoietic Cell Transplantation Outcomes. TANDEM Meetings of ASTCT and CIBMTR, 2025. e-Pub 2025.
28. Popat UR, Alousi AM, Bassett RL, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Shigle TL, Smallbone P, Srour SA, Champlin RE, Shpall EJ. Jak Inhibitor Itacitinib with Ptcy and Tacrolimus to Prevent Gvhd in a Myeloablative Fractionated Busulfan Regimen: A Phase 2 Trial. TANDEM Meetings of ASTCT and CIBMTR 2025, 2025. e-Pub 2025.
29. Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Siddiqui UR, Khan HN, Haider AA, Ramdial JL, Nieto Y, Tang G, Lakhani K, Aljawai YM, Kebriaei P, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Daratumumab-Based Second Line Therapy Improves Outcomes after VRD Induction, Upfront Autologous Transplant and Lenalidomide Maintenance. TANDEM Meetings of ASTCT and CIBMTR 2025, 2025. e-Pub 2025.
30. Pasvolsky O, Nieto Y, Orlowski R, Bashir Q, Milton D, Becnel M, Tanner M, Qazilbash M, Tang G, Champlin R, Ramdial J, Saini N, Thomas S, Saeed A, Haider A, Lee H, Shpall E, Lin P, Patel K, Kebriaei P, Srour S, Aljawai Y. Outcomes of Patients with IgD Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant. TANDEM Meetings of ASTCT and CIBMTR, 2025. e-Pub 2025.
31. Hosing C, Nieto Y, Andersson B, Bashir Q, Bazinet A, Qazilbash M, Chen G, Champlin R, Marin D, Alousi A, Olson A, Ramdial J, Oran B, Saini N, Alatrash G, Im J, Shpall E, Garcia-Manero G, Fingrut W, Kebriaei P, Srour S, Aljawai Y, Saliba R, Popat U, Smallbone P. Allogeneic Stem Cell Transplant with Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Conditioning Regimen in Older Patients with High Risk MDS. TANDEM Meetings of ASTCT and CIBMTR 2025, 2025. e-Pub 2025.
32. Alatrash G, Knape C, Whited L, Sui D, Haymaker CL, Yeh J, Marcotulli M, Sukhumalchandra P, John LS, Lu H, Duenas DE, Wistuba I, Perez JM, Espiridion BS, Bassett RL, Kadia TM, DiNardo CD, Ravandi F, Ramdial J, Mehta RS, Alousi AM, Oran B, Khouri IF, Bashir Q, Hosing C, Qazilbash MH, Im JS, Kebriaei P, Bachireddy P, Molldrem JJ, Jorgensen JL, Wang SA, Wang W, Popat U, Shpall EJ, Champlin RE, Kantarjian HM, Daver N. A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation. 66th ASH Annual Meeting & Exposition, 2024. e-Pub 2024.
33. Cervoni Curet FN, Bassett RL, Pasvolsky O, Deen AF, Tanner MR, Bashir Q, Srour SA, Saini NY, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Fingrut WB, Smallbone P, Becnel MR, Gaballa MR, Thomas SK, Ye J, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma. 66th ASH Annual Meeting & Exposition, 2024. e-Pub 2024.
34. Srour SA, Saliba RM, Ramdial J, Smallbone P, Im JS, Olson AL, Kusy CC, Oran B, Chen G, Qazilbash MH, Kebriaei P, Hosing C, Khouri IF, Alousi AM, Bashir Q, Marin D, Nieto Y, Shpall EJ, Champlin RE, Popat U. Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis. 66th ASH Annual Meeting & Exposition, 2024. e-Pub 2024.
35. Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Patel A, Khan HN, Ramdial J, Nieto Y, Tang G, Haider A, Aljawai YM, Ahmed S, Kebriaei P, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant. 66th ASH Annual Meeting & Exposition, 2024. e-Pub 2024.
36. Popat U, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen G, Fingrut WB, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial J, Saini NY, Smallbone P, Srour SA, Valdez BC, Champlin RE, Andersson BS, Shpall EJ. Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial. 66th ASH Annual Meeting & Exposition, 2024. e-Pub 2024.
37. Deen AF, Bashir Q, Saini NY, Aljawai YM, Hosing C, Popat U, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Srour SA. Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis. 66th ASH Annual Meeting & Exposition, 2024. e-Pub 2024.
38. Sami SS, Bashir Q, Saini NY, Aljawai YM, Hosing C, Popat U, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Srour SA. Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis. 66th ASH Annual Meeting & Exposition, 2024. e-Pub 2024.
39. Oran B, Marin D, Bashir Q, Ahmed S, Olson AL, Popat U, Kebriaei P, Shpall EJ, Jain V, Champlin RE. Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML. 66th ASH Annual Meeting & Exposition, 2024. e-Pub 2024.
40. Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Lee H, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center. 65th ASH Annual Meeting & Exposition, 2023. e-Pub 2023.
41. Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Khan HN, Kebriaei P, Lee H, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience. 65th ASH Annual Meeting & Exposition, 2023. e-Pub 2023.
42. Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri IF, Srour SA, Champlin RE, Shpall EJ, Kebriaei P. Incidence and Risk Factors of Veno-Occlusive Disease Are Different in Younger Versus Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. 65th ASH Annual Meeting & Exposition, 2023. e-Pub 2023.
43. Qazilbash MH, Khan HN, Milton DR, Pasvolsky O, Tanner MR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Bashir Q, Pemmaraju N. Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). 65th ASH Annual Meeting & Exposition, 2023. e-Pub 2023.
44. Bashir Q, Thall P, Sui D, Kawedia J, Knape C, Delgado R, Schindler JL, Popat UR, Kebriaei P, Hosing C, Khouri IF, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Lee H, Thomas SK, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. 65th ASH Annual Meeting & Exposition, 2023. e-Pub 2023.
45. Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Lee H, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation. 65th ASH Annual Meeting & Exposition, 2023. e-Pub 2023.
46. Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Lee H, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation. 65th ASH Annual Meeting & Exposition, 2023. e-Pub 2023.
47. Saengbon S, Carmona SN, Bashir Q, Al-Atrash G, Cox N, Borthakur G, Vickers MR, Ramdial J, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Srour SA. Impact of Smoking on Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation, 2023. e-Pub 2023.
48. Lee HC, Kaufman GP, Feng L, Murga A, Johnson RJ, Weber DM, Thomas SK, Bashir Q, Qazilbash MH, Iyer SP, Patel K, Becnel MR, Manasanch EE, Orlowski RZ. Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis. 64th ASH Annual Meeting & Exposition 140(Supplement 1):4428-4430, 2022. e-Pub 2022.
49. Ozcan G, Popat UR, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Mehta RS, Ramdial JL, Rondon G, Shpall EJ, Champlin RE, Oran B. Transplant Outcomes for TP53 AML and MDS in a Contemporary Era. 64th ASH Annual Meeting & Exposition 140(Supplement 1):10621, 2022. e-Pub 2022.
50. Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi AM, Olson AL, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short N, Ravandi F, Champlin RE, Shpall EJ, Kebriaei P. Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond. 64th ASH Annual Meeting & Exposition, 2022. e-Pub 2022.
51. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. 64th ASH Annual Meeting & Exposition 140(Supplement 1):10530-10531, 2022. e-Pub 2022.
52. Champlin RE, Lustig EB, Bashir Q, Oran B, Kornblau SM, Hosing C, Alousi AM, Popat UR, McCarty JM, Thall PF, Dabaja BS, Liu W, Dang G, Castro K, Ramirez A, Spiotto M, Wu S, Fang P, Kaur I, Rezvani K, Shpall EJ, Reisner Y. First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT). 64th ASH Annual Meeting & Exposition 140(Supplement 1):2120-2122, 2022. e-Pub 2022.
53. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. 64th ASH Annual Meeting & Exposition, 2022. e-Pub 2022.
54. Oran B, Champlin RE, Thall PF, McCarty JM, Zhang W, Marin D, Mehta RS, Alousi AM, Alatrash G, Popat UR, Kantarjian H, Bashir Q, Shpall EJ, Konopleva M. Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT). 64th ASH Annual Meeting & Exposition 140(Supplement 1):10561-10562, 2022. e-Pub 2022.
55. Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour SA, Saini N, Lin P, Ramdial JL, Nieto Y, Tang G, Lee HC, Patel K, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Shpall EJ, Champlin RE, Lin P, Qazilbash MH. Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. 64th ASH Annual Meeting & Exposition 140(Supplement 1):284-286, 2022. e-Pub 2022.
56. Pasvolsky O, Milton DR, Masood A, Shehzad SS, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial JL, Nieto Y, Lee HC, Patel K, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience. 64th ASH Annual Meeting & Exposition 140(Supplement 1):10589-10591, 2022. e-Pub 2022.
57. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT. 64th ASH Annual Meeting & Exposition 140(Supplement 1):4880-4881, 2022. e-Pub 2022.
58. Popat UR, Mehta RS, Basset R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial, 2021. e-Pub 2021.
59. Nelson BE, Ramdial JL, Bashir Q, Saini N, Hosing C, Popat UR, Delgado R, Lee HC, Kaufman GP, Orlowski RZ, Champlin RE, Qazilbash MH, Srour SA. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy, 2021. e-Pub 2021.
60. UR Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis A, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial, 2021. e-Pub 2021.
61. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri I, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial, 2021. e-Pub 2021.
62. Bashir Q, Thall PF, Sui D, Ramdial JL, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini N, Kebriaei P, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Patel KK, Orlowski RZ, Knape CG, Kawedia JD, Champlin RE, Shpall EJ, Lu X, Qazilbash MH. A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma, 2021. e-Pub 2021.
63. Popat UR, Bassett R, Thall PF, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS, Mehta RS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial, 2021. e-Pub 2021.
64. Nelson BE, Ramdial JL, Bashir Q, Saini N, Hosing C, Popat UR, Delgado R, Lee HC, Kaufman GP, Orlowski RZ, Champlin RE, Qazilbash MH, Srour SA. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. 63rd ASH Annual Meeting & Exposition, 2021. e-Pub 2021.
65. Al-Juhaishi T, Al-Juhaishi T, Malek AE, Malek AE, Milton DR, Milton DR, Ramdial JL, Ramdial JL, Daher M, Daher M, Olson AL, Olson AL, Srour SA, Srour SA, Alatrash G, Alatrash G, Oran B, Oran B, Mehta RS, Mehta RS, Khouri IF, Khouri IF, Bashir Q, Bashir Q, Shah N, Shah N, Ciurea SO, Ciurea SO, Rondon G, Rondon G, Maadani F, Maadani F, Hosing C, Hosing C, Marin D, Marin D, Kebriaei P, Kebriaei P, Rezvani K, Rezvani K, Nieto Y, Nieto Y, Anderlini P, Anderlini P, Alousi AM, Alousi AM, Qazilbash MH, Qazilbash MH, Popat UR, Popat UR, Champlin RE, Champlin RE, Shpall EJ, Shpall EJ, Mulanovich V, Mulanovich V, Ahmed S, Ahmed S. Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell TransplantationT. 63rd ASH Annual Meeting & Exposition 138(Supplement 1):1779, 2021. e-Pub 2021.
66. Bashir Q, Bassett R, Thall PF, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS, Mehta RS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. 63rd ASH Annual Meeting & Exposition 138(Supplement 1):556, 2021. e-Pub 2021.
67. Bashir Q, Thall PF, Sui D, Ramdial JL, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini N, Kebriaei P, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Patel KK, Orlowski RZ, Knape CG, Kawedia JD, Champlin RE, Shpall EJ, Liu X, Qazilbash MH. A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. 63rd ASH Annual Meeting & Exposition 138(Supplement 1):3941, 2021. e-Pub 2021.
68. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis A, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. 63rd ASH Annual Meeting & Exposition, 2021. e-Pub 2021.
69. Mohamed SF, Khan M, Quesada A, Ma J, Lin P, Yin C, Sasaki K, Borthakur G, Pemmaraju N, Bashir Q, Qazilbash MH, Kaufman GP, Becnel MR. Disease Characteristics of Multiple Myeloma Involving BRAF Mutations. 63rd ASH Annual Meeting & Exposition, 2021. e-Pub 2021.
70. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. 63rd ASH Annual Meeting & Exposition, 2021. e-Pub 2021.
71. Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EE, Olsem JB, Morphey AN, Huo XJ, Bashir Q, Thomas SK, Qazilbash MH, Weber DM, Orlowski RZ. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-Transplant Myeloma Patients. 63rd ASH Annual Meeting & Exposition, 2021. e-Pub 2021.
72. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. 63rd ASH Annual Meeting & Exposition, 2021. e-Pub 2021.
73. Ramdial JL, Gaballa MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Weber DM, Kaufman GP, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. Blood 136(Supplement 1):11-13, 2020. e-Pub 2020.
74. Afrough A, Alsfeld LC, Delgado R, Popat UR, Kebriaei P, Oran B, Saini N, Srour SA, Hosing C, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Blood 136(Supplement 1):22-22, 2020. e-Pub 2020.
75. Bashir Q, Rezvani K, Saini N, Shpall EJ, Srour SA, Popat UR, Milton DR, Pemmaraju N, Champlin RE, Qazilbash MH. Phase 2 Study of Tagraxofusp Therapy for BPDCN Patients Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation. Blood 136(Supplement 1):5-5, 2020. e-Pub 2020.
76. Gaballa MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. Blood 136(Supplement 1):14-15, 2020. e-Pub 2020.
77. Saini N, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Srour SA, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis 136(Supplement 1):9-10, 2020. e-Pub 2020.
78. Bashir Q, Thall PF, Sui D, Knape C, Kawedia J, Qazilbash MH. Trial in Progress: A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. Blood 136(Supplement 1):37-38, 2020. e-Pub 2020.
79. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Ciurea SO, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Hosing C, Patel KK, Lee HC, Shpall EJ, Orlowski RXZ Champlin RE, Qazilbash MH. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. Blood 136(Supplement 1):23-24, 2020. e-Pub 2020.
80. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Hosing C, Ciurea SO, Daher M, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Kaufman GP, Patel KK, Shpall EJ, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. Blood 136(Supplement 1):24-25, 2020. e-Pub 2020.
81. Afrough A, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 136(Supplement 1):20-21, 2020. e-Pub 2020.
82. Afrough A, Alsfeld LC, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 136(Supplement 1):18-19, 2020. e-Pub 2020.
83. Ramdial JL, Ma J, Milton DR, Delgado R, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Kaufman GP, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. Blood 136(Supplement 1):6-7, 2020. e-Pub 2020.
84. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Alatrash G, Bashir Q, Ciurea S, Hosing C, Im JS, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. Blood 136(Supplement 1):10-11, 2020. e-Pub 2020.
85. Andersson BS, Thall P, Valdez BC, Ma J, Chen J, Ahmed S, Alousi AM, Bashir Q, Ciurea SO, Gulbis A, Hosing C, Jones RB, Kawedia J, Kebriaei K, Kornblau SM, Myers A, Oran B, Rezvani K, Shah N, Shpall EJ, Parmar S, Popat UR, Nieto Y, Champlin RE. A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. Blood 136(Supplement 1):37-38, 2020. e-Pub 2020.
86. Manasanch EE, Han G, Zhang Z, Dang M, Singh M, Khan M, Singh S, Lee HC, Patel KK, Kaufman GP, Amini B, Bashir Q, Srour SA, Nieto Y, Qazilbash MH, Berkova Z, Lin P, Berry D, Thomas SK, Weber DM, Futreal PA, Wang L, Orlowski RZ, Neelapu SS. Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma. Blood 136(Supplement 1):37-38, 2020. e-Pub 2020.
87. Khouri IF, Gruschkus SK, Gulbis A, Ledesma C, Jain N, Kadia TM, Pemmaraju N, Anderlini P, Bashir Q, Daher M, Kebriaei P, Marin D, Mehta R, Popat UR, Saini N, Srour SA, Im JS, Fayad L, Nair R, Iyer SP, Strati P, Samaniego F, Nastoupil LJ, Flowers C, Rondon G, Kantarjian HM, Champlin RE, Jabbour E. Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. Blood 136(Supplement 1):10-12, 2020. e-Pub 2020.
88. Thomas SK, Shah JJ, Morin A, Morphey AN, Lee HC, Manasanch EE, Patel KK, Kaufman GP, Iyer SP, Feng L, Amini B, Qazilbash MH, Bashir Q, Saini N, Srour SA, Johnson RJ, Crumpton BN, Stafford MD, Weber DM, Orlowski RZ. Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). Blood 136(Supplement 1):46-47, 2020. e-Pub 2020.
89. Khouri IF, Gruschkus SK, Ledesma C, Anderlini P, Bashir Q, Daher M, Iyer SP, Marin D, Mehta R, Olson AL, Popat UR, Samaniego F, Qazilbash MH, Im JS, Rondon G, Champlin RE, Gulbis A, Young KH. Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma. Blood 136(Supplement 1):24-25, 2020. e-Pub 2020.
90. Khouri IF, Milton DR, Ledesma C, Jabbour E, Bashir Q, Im JS, Fayad L, Lee HJ, Nair R, Nastoupil LJ, Samaniego F, Iyer SP, Flowers C, Champlin RE, Sharma P, Gulbis A. Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma. Blood 136(Supplement 1):9-11, 2020. e-Pub 2020.
91. Yalniz FF, Saliba RM, Yucel OK, Garcia-Manero G, Ramdial J, Popat U, Ciurea SO, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Hosing C, Marin D, Mehta R, Olson AL, Rezvani K, Shpall EJ, Rondon G, Champlin RE, Oran B. Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation, 2019. e-Pub 2019.
92. Khouri IF, Milton DR, Ledesma C, Nastoupil LJ, Jabbour E, Anderlini P, Bashir Q, Ciurea SO, Daher M, Fayad LE, Im JS, Iyer SP, Marin D, Mehta RS, Molldren J, Olson AL, Oran B, Popat U, Qazilbash M, Srour S, Samaniego F, Rondon G, Jeffrey M, Gulbis A. Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL), 2019. e-Pub 2019.
93. Champlin RE, Popat U, Oran B, Ciurea SO, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Khouri IF, Hosing C, Anderlini P, Jones RB, Marin D, Mehta R, Nieto Y, Olson AL, Qazilbash MH, Rezvani K, Shpall EJ, Chen J, Rondon G, McMullin B, Al Jahdhami VP, Kawedia J, Valdez BC, Ma J, Thall PF, Andersson BS. A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS, 2019. e-Pub 2019.
94. Popat U, Mehta RS, Bassett R, Olson AL, Chen J, Ganesh C, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Seon-Im J, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash Q, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study, 2019. e-Pub 2019.
95. Ciurea SO, Verma A, Kongtim P, Srour S, Bashir Q, Alousi AM, Mehta RS, Oran B, Popat U, Hosing C, Rondon G, Chen J, Olson AL, Konopleva MY, Champlin RE. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis, 2019. e-Pub 2019.
96. Popat U, Saliba RM, Mehta RS, Olson AL, Chen J, Ganesh C, Rondon G, Woodworth G, McMullin B, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis i, 2019. e-Pub 2019.
97. Mukherjee A, Milton DR, Gulbis A, Ledesma C, Jabbour EK, Alousi AM, Bashir Q, Daher M, Oran BN, Olson AL, Marin D, Srour S, Kebriaei P, Mehta RS, Nemeth KP, Popat U, Im JS, Champlin RE, Khouri IF. Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Donor (MUD) Transplantation in Patients (pts) with Relapsed/Refractory Lymphoma, 2019. e-Pub 2019.
98. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta RS, Kaufman GP, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Retrospective Analysis, 2019. e-Pub 2019.
99. Ciurea SO, Bassett R, Soebbing D, Rondon G, Cao K, Olson AL, Bashir Q, Shpall EJ, Devine S, Pasquini MC, St Martin A, Lee DA, Champlin R. Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls, 2019. e-Pub 2019.
100. Wang Y, Young KH, Milton DR, Ledesma C, Jabbour E, Xu-Monette ZY, Molldrem JJ, Anderlini P, Alousi AM, Bashir Q, Daher M, Fayad LE, Iyer SP, Kebriaei P, Marin D, Mehta RS, Olson AL, Popat U, Samaniego F, Westin JR, Qazilbash MH, Im JS, Rondon G, Gulbis A, Champlin RE, Khouri IF. Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation, 2019. e-Pub 2019.
101. Ciurea SO, Saliba RM, Soebbing D, Rondon G, Cao K, Olson A, Bashir Q, Shpall EJ, Lee D, Champlin RE. Outcomes with High-Doses of Vivo Expanded NK Cells after Haploidentical Stem Cell Transplantation (haploSCT), 2019. e-Pub 2019.
102. Srour SA, Milton D, Bashir Q, Mehta RS, Delgado R, Rondon G, Nieto Y, Hosing CM, Popat UR, Ciurea SO, Patel K, Lee HC, Manasanch E, Thomas S, Weber D, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan Dose Intensity for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma, 2019. e-Pub 2019.
103. Mukherjee A, Milton D, Ledesma C, Olson A, Al-Atrash G, Anderlini P, Alousi AM, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Molldrem JJ, Oran B, Popat UR, Qazilbash MH, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Influence of the Intensity of the Allogeneic Conditioning Regimen on the Risk of Hemorrhagic Cystitis (HC) in Patients Receiving Post- Transplant Cyclophosphamide (PT-Cy) As Gvhd Prophylaxis, 2019. e-Pub 2019.
104. Varma A, Abraham SC, Saini N, Bashir Q, Rondon G, Srour SA, Mehta RS, Olson A, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Shpall EJ, Champlin RE, Popat UR. Idiopathic Portal Hypertension Related Refractory Ascites (IPHRA) after Allogeneic Stem Cell Transplant, 2019. e-Pub 2019.
105. Kawedia JD, Ramachandran S, Gulbis AM, Titus M, Bashir Q, Qazilbash MH, Champlin RE, Ciurea SO. Stability of Captisol-Enabled Melphalan (Evomela) in 0.9% Sodium Chloride Solution in IV Bags and Glass Vials at Room Temperature and Refrigeration, 2019. e-Pub 2019.
106. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Conditioning Using Timed Sequential Busulfan in Older Patients with Acute Myeloid Leukemia: Long Term Results of a Prospective Phase II Clinical Trial, 2019. e-Pub 2019.
107. Oran B, Ciurea SO, Marin D, McCarty JM, Bashir Q, Ahmed S, Olson AL, Popat U, Nieto Y, pa K, Shpall EJ, Agrawal T, Champlin RE. Safety Analysis of Intra-Patient Dose-Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant. Blood 132(Suppl 1):3426, 2018. e-Pub 2018.
108. Varma A, Saini NY, Sui D, Milton DR, Hasan O, Mukherjee A, Bashir Q, Rondon G, Srour SA, Popat U, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Khouri IF, Weber DM, Thomas SK, Manasanch EE, Lee HC, Patel KK, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after igh-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. Blood 132(Suppl 1):4609, 2018. e-Pub 2018.
109. Saini NY, Varma A, Ma J, Milton DR, Patel R, Hasan O, Bashir Q, Nieto Y, Mukherjee A, Delgado R, Rondon G, Popat U, Hosing C, Kebriaei P, Alousi AM, Ahmed S, Mehta RS, Ciurea SO, Khouri IF, Shpall EJ, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. Blood 132(Suppl 1):4607, 2018. e-Pub 2018.
110. Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Alatrash G, Alousi AM, Andersson BS, Im JS, Hosing C, Bashir Q, Khouri IF, Kebriaei P, Oran B, Popat U, Champlin RE, Ciurea SO. Hematopoietic Cell Transplant-Composite Risk (HCT-CR) - a Novel Prognostic Model to Predict Transplant Outcomes. Blood 132(Suppl 1):2141, 2018. e-Pub 2018.
111. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Blood 132(Suppl 1):2144, 2018. e-Pub 2018.
112. Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva MY, Perez JMR, Elshazly M, Alijadayeh M, Alvarez M, Im JS, Alatrash G, Mehta RS, Popat U, Bashir Q, Oran B, Hosing C, Khouri IF, Kebriaei P, Champlin RE. Is a Matched Unrelated Donor Search Needed for All Allogeneic Transplant Candidates?. Blood 132(Suppl 1):3450, 2018. e-Pub 2018.
113. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Oran B, Hosing C, Bashir Q, Olson AL, Nieto Y, Alousi AM, Kebriaei P, Srour SA, Mehta RS, Anderlini P, Shpall, EJ, Qazilbash MH, Khouri IF, Fayad LE, Lee HJ, Fowler NH, Parmar S, Westin JR, Hagemeister FB, Champlin RE, Ciurea SO. Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types. Blood 132(Suppl 1):3356, 2018. e-Pub 2018.
114. Popat U, Mehta RS, Bassett Jr RL, Olson AL, Chen J, Ahmed S, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Anderssson BS. Timed Sequential Busulfan and Post-Transplantation Cyclophosphamide in Matched and Haploidentical Transplantation: Results of a Phase II Study. Blood 132(Suppl 1):3373, 2018. e-Pub 2018.
115. Khouri IF, Milton DR, Ledesma C, Eerwin WD, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Im JS, Marin D, Mehta RS, Molldrem JJ, Olson AL, Oran, B, Popat U, Qazilbash MH, Rondon G, Champlin RE, Medeiros J, Gulbis A. Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17-Year Experience. Blood 132(Suppl 1):4651, 2018. e-Pub 2018.
116. Saini NY, Patel R, Varma A, Bashir Q, Hasan O, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Mansanch EE, Orlowski RZ, Chmaplin RE, Qazilbash MH, Patel KK. Long-Term Durable Responses after Autologous Stem Cell Transplantation in POEMS Syndrome. Blood 132(Suppl 1):4606, 2018. e-Pub 2018.
117. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Popat U, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mukherjee A, Mehta RS, Khouri IF, Ciurea SO, Shpall EJ, Hasan O, Weber DM, Sk T, Lee HC, Manasanch, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-Bsaed Autologous Transplantation in the Octogenarian Multiple Myeloma Patient Population. Blood 132(Suppl 1):4608, 2018. e-Pub 2018.
118. Khouri IF, Milton DR, Ledesma C, Jabbour EJ, Alatrash G, Anderlini P, Alousi AM, Bashir Q, Ciurea SO, Hymes S, Marin D, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash MH, Rondon G, Champlin RE. Influence of the Intensity of the Conditioning Regimens on the Risks of Gvhd in Patients Receiving Rituximab Prophylaxis during Allogeneic Stem Cell Transplantation (alloSCT). Blood 132(Suppl 1):4584, 2018. e-Pub 2018.
119. Patel R, Saini NY, Varma A, Hasan O, Bashir Q, Delgado R, Popat U, Hosing C, Mukherjee A, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Mansanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcome of Autologous Stem Cell Transplantation in Waldenstrom's Macroglobulinemia. Blood 132(Suppl 1):2149, 2018. e-Pub 2018.
120. Oran B, de Lima M, Garcia Manero G, Thall PF, Lin R, Alousi AM, Hosing C, Kebriaei P, Popat U, Giralt S, Ahmed S, Shpall EJ, Andersson BS, Bashir Q, Ciurea SO, Rezvani K, Woodworth G, Champlin RE. Maintenance with 5-Azacytidine fo rAcute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Blood 132(Suppl 1):971, 2018. e-Pub 2018.
121. Oran B, Saliba RM, Jorgensen JL, Shah MV, Marin DC, Wang SA, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Rezvani K, Popat U, Rondon G, Kebriaei P, Shpall EJ, Champlin RE. The Prognostic Impact of Minimal Residual Disease on Risk of Progression and Progression Free Survival in Acute Myeloid Leukemia. Blood 130(Suppl 1):2031, 2017. e-Pub 2017.
122. Manasanch EE, Claussen CM, Dong W, Lee HC, Thomas SK, Patel KK, Reed VK, Dabaja BS, Milgrom S, Pinnix CC, Parmar S, Bashir, Q, Qazilbash MH, Amini B, Raymond A, Orlowski RZ, Feng L, Weber, DM. A Clinical Model of Progression to Multiple Myeloma in Solitary Plasmacytoma. Blood 130(Suppl 1):5367, 2017. e-Pub 2017.
123. Patel KK, Shah JJ, Feng L, Lee HC, Mansanch EE, Thomas SK, Weber DM, Munoz SC, Morphey A, Bashir Q, Qazilbash MH, Orlowski RZ. Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autolous Stem Cell Transplant in Patients with Multiple Myeloma. Blood 130(Suppl 1):437, 2017. e-Pub 2017.
124. Kongtim P, Parmar S, Milton DR, Rondon G, Chen J, Oran B, Popat U, Hosing C, Bashir Q, Kebriaei P, Khouri IF, Champlin RE, Ciurea SO. Validation of a Predictive Model for Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Receiving Hematopoietic Stem Cell Transplantation. Blood 130(Suppl 1):4511, 2017. e-Pub 2017.
125. Kongtim P, Parmar S, Milton DR, Rondon G, Chen J, Oran B, Popat U, Hosing C, Bashir Q, Kebriaei P, Khouri IF, Champlin RE, Ciurea SO. Validation of a Predictive Model for Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Receiving Hematopoietic Stem Cell Transplantation. Bood 130(Suppl 1):4511, 2017. e-Pub 2017.
126. Srour S, Desai P, Ciurea SO, Bashir Q, Oran B, Olson AL, Ahmed S, Bose P, Mehta RS, Pemmaraju N, Verstovsek S, Champlin RE, Popat U. Myeloid Mixed Chimerism and Relapse in Myelofibrosis after Allogeneic Stem Cell Transplant. Blood 130(Suppl 1):2007, 2017. e-Pub 2017.
127. Malek E, Creger R, Kolk M, Covut F, Champlin R E, Cooper B W, Caimi P, Lazarus H M, Gupta V, Vatsayan A, Bashir Q, de Lima M, Qazilbash M H. Reducing Gastrointestinal Toxicity Associated with Autologous Transplantation for Multiple Myeloma without Compromising Its Anti-Myeloma Effect. Blood 130(Suppl 1):680, 2017. e-Pub 2017.
128. Williams LA, Qazilbash MH, Shi Q, Bashir Q, Lin HK, Cleeland CS, Champlin RE. Symptom Burden of Busulfan and Melphalan Versus Melphalan Alone for Multiple Myeloma. Blood 130(Suppl 1):681, 2017. e-Pub 2017.
129. Ciurea SO, Soebbing D, Rondon G, Cao K, Alatrash G, Ahmed S, Popat U, Oran B, Bashir Q, Kebriaei P, Kaur I, Rezvani K, Shpall EJ, Lee DA, Champlin RE. Interim Results of a Phase 2 Clinical Trial Using Mb-IL21 Ex Vivo Expanded NK Cells to Enhance Graft Versus Leukemia Effect for Patients with Myeloid Malignancies after Haploidentical Transplantation. Blood 130(Suppl 1):3179, 2017. e-Pub 2017.
130. Qazilbash MH, Bashir Q, Thall PF, Milton DR, Shah N, Patel KK, Andersson BS, Nieto Y, Kebriaei P, Valdez BC, Kawedia J, Parmar S, Delgado R, Ahmed S, Hosing C, Popat U, Shpall EJ, Weber DM, Thomas SK, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE. A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma. Blood 130(Suppl 1):399, 2017. e-Pub 2017.
131. Gowda L, Saliba RM, Shah MV, Rondon G, Badar I, Olson AL, Ciurea SO, Kebriaei P, Srour SA, Parmar S, Nieto Y, Ahmed S, Mehta RS, Alatrash G, Marin DC, Andersson BS, Oran B, Bashir Q, Qazilbash MH, Hosing C, Khouri IF, Alousi AM, Anderlini P, Shpall EJ, Rezvani K, Champlin RE, Popat U. Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival. Blood 130(Suppl 1):3267, 2017. e-Pub 2017.
132. Qazilbash MH, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross B, Honhar M, Cha SC, Kim K, Popescu M, Shah N, Bashir Q, Patel KK, Lee VY, Shpall EJ, Weber DM, Thomas SK, Orlowski RZ, Kerr N, Garfall AL, Cohen AD, Vogl DT, Dengel K, June CH, Champlin RE, Kwak LW. Randomized Phase II Trial of Combination Idiotype Vaccine and Adoptive Cell Transfer of Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. Blood 130(Suppl 1):3193, 2017. e-Pub 2017.
133. Claussen CM, Chuang T, Chaudhry M, Lee HC, Patel KK, Bashir Q, Parmar S, Ahmed S, Mehta RS, Thomas SK, Richards TA, Nieto Y, Shpall EJ, Qazilbash MH, Amini B, Davis RE, Neelapu SS, Weber DM, Orlowski RZ, Feng L, Manasanch EE. Gene Expression Profiling Is a Strong Predictor of Clinical Outcomes in Newly Diagnosed Multiple Myeloma. Blood 130(Suppl 1):4365, 2017. e-Pub 2017.
134. Ciurea SO, Saliba RM, Chen J, Rondon G, Popat U, Parmar S, Anderson B, Alousi AM, Ahmed S, Bashir Q, Alatrash G, Hosing C, Olson AL, Mehta RS, Rezvani K, Shpall EJ, Khouri IF, Kebriaei P, Champlin RE. Allogeneic Transplantation for TP53+ AML: Prognostic Factors for Survival. Blood 130(Suppl 1):1938, 2017. e-Pub 2017.
135. Maymani H, Popat UR, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing CM, Ciurea SO, Andersson BS, Shpall EJ, Champlin RE, Qazilbash MH. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biology of Blood and Marrow Transplantation 23(3):S289-S290, 2017. e-Pub 2017.
136. Shah MV, Saliba R, Jorgensen JL, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients. Biology of Blood and Marrow Transplantation 23(3):S40-S41, 2017. e-Pub 2017.
137. Chen CE, Mao AY, Murray JG, Oran B, Qazilbash MH, Shah N, Ahmed S, Bashir Q, Hosing C, Shpall EJ, Steele JR, Champlin RE, Parmar S. Feasibility of a Smartphone-Based Health Coaching Intervention for Patient Self-Management of Nutrition in the Post-Chemotherapy Setting. Blood 128(22):3554, 2016. e-Pub 2016.
138. Qazilbash M, Stadtmuer E, Baladandayuthapani V, Lin H, Tross B, Honhar M, Cha S, Kim K, Rao S, Popescu M, Shah N, Bashir Q, Patel K, Shpall E, Weber D, Thomas S, Shah J, Orlowski R, Kerr N, Garfall A, Cohen A, Dengel K, June C, Champlin R, Kwak L. Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologus T Cells in Patients with Multiple Myeloma Post-Autotransplantation. Blood 128(22):4548, 2016. e-Pub 2016.
139. Srour SA, Saliba RM, Delgado R, Qazilbash MH, Bashir Q, Shah N, Popat UR, Ahmed S, Patel K, Jones R, Rondon G, Champlin RE, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Blood 128(22):3314, 2016. e-Pub 2016.
140. Shah N, Giralt SA, Shi Q, Williams LA, Bashir Q, Qazilbash M, Champlin RE, Clkeeland CS, Wang XS. Patient-Reported Outcomes and Patient-Performed Testing in Measuring Functional Impairment after Stem Cell Transplant in Patients with Multiple Myeloma. Blood 128(22):538, 2016. e-Pub 2016.
141. Claussen CM, Lee H, Shah JJ, Richards T, Shah N, Patel K, Bashir Q, Parmar S, Thomas S, Nieto Y, Qazilbash MH, Davis RE, Neelapu SS, Weber DM, Orlowski RZ, Feng L, Manasanch EE. Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard Care Setting. Blood 128(22):5628, 2016. e-Pub 2016.
142. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat UR, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B. Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning in Older Patients with Myelodysplastic Syndromes. Blood 128(22):5847, 2016. e-Pub 2016.
143. Cornelison MA, Saliba RM, Ahmed S, Nieto Y, Bashir Q, Shah N, Parmar S, Patel K, Hosing C, Popat UR, Shpall EJ, Champlin RE, Qazilbash MH. Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 128(22):5884, 2016. e-Pub 2016.
144. Mohyuddin GR, Faisal MS, Shah N, Bashir Q, Hosing C, Patel K, Popat UR, Parmar S, Rondon G, Delgado R, Weber DM, Shah JJ, Thomas S, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson. Blood 128(22):4613, 2016. e-Pub 2016.
145. Shah N, Thall PF, Milton DR, Bashir Q, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing C, Cornelison MA, Delgado R, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash M. Phase I/II of Lenalidomide and High-Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma: Updated Results. Blood 128(22):2269, 2016. e-Pub 2016.
146. Bashir Q, Shazly ME, Milton DR, Patel K, Shah N, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea SO, Hosing C, Lee H, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Autologous Stem Cell Transplantation in Myeloma Patients Aged ≥ 75 Years. Blood 128(22):3453, 2016. e-Pub 2016.
147. Veltri LW, Milton DR, Shah N, Patel K, NIeto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea SO, Hosing C, Lee H, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of Autologous Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Multiple Myeloma. Blood 128(22):4626, 2016. e-Pub 2016.
148. Ciurea SO, Lee DA, Denman C, Schafer J, Bassett Jr RL, Cao K, Rondon G, Chen J, Soebbing D, Willis DB, Ahmed S, Bashir Q, Kebriaei P, Khour IF, Oran B, Parmar S, Popat UR, Hosing C, Yvon E, Rezvani K, Shpall EJ, Champlin RE. Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial. Blood 128(22):500, 2016. e-Pub 2016.
149. Yucel OK, Saliba RM, Rondon G, ahmed S, Alousi AM, Andersson BJ, Bashir Q, Ciurea SO, Khouri IF, Nieto Y, Popat UR, Marin D, Rezvani K, Kebriaei P, Shah N, Olson AL, Shpall EJ, Champlin RE, Oran B. Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 128(22):2276, 2016. e-Pub 2016.
150. Sasaki K, Bashir Q, Shah N, Hosing C, Popat UR, Nieto Y, Parmar S, Shah J, Weber D, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation 22(3):S231-S232, 2016. e-Pub 2016.
151. Qazilbash MH, Chen J, Valdez BC, Sasaki K, Kawedia JD, Bashir Q, Hosing C, Kebriaei P, NIeto Y, Shah N, Patel K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Timed Sequential Busulfan Is Safe in Patients with Relapsed or High-Risk Multiple Myeloma. Biology of Blood and Marrow Transplantation 22(3):S228-S229, 2016. e-Pub 2016.
152. Badar T, Bashir Q, Shah N, Alatrash G, Hosing C, Popat UR, Nieto Y, Shah J, Orlowski RZ, Champlin RE, Qazilbash MH. Predictors of Inferior Clinical Outcome in Patients with Standard Risk Multiple Myeloma. Biology of Blood and Marrow Transplantation 22(3):S216-S217, 2016. e-Pub 2016.
153. Shah J, Feng L, Manasanch E, Weber D, Thomas S, Turturro F, Shah N, Popat U, Nieto Y, Bashir Q, Munoz S, Landry A, Mendoza K, Champlin R, Qazilbash M, Orlowski R. Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. Blood 126(23):187, 2015. e-Pub 2015.
154. Kebriaei P, Basset R, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin R, Andersson. Clofarabine (Clo) Plus Busulfan (Bu) is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results. Blood 126(23):4376, 2015. e-Pub 2015.
155. Oran B, Jorgensen J, Wang S, Marin D, Popat U, Chen J, Ciurea S, Ahmed S, Bashir Q, Rezvani K, Shpall E, Kebriaei P, Champlin R. Minimal Residual Disease Detected by Multiparameter Flow Cytometry and Complex Karyotype are the Major Prognostic Factors for Relapse after HCT. Blood 126(23):4342, 2015. e-Pub 2015.
156. Ramlal R, Gaballa S, Chen J, Rondon G, Oran B, Ahmed S, Bashir Q, Rezvani K, Marin D, Alousi A, Kebriaei P, Qazilbash M, Hosing C, Popat U, Shpall E, Champlin R, Ciurea S. Outcomes of Haploidenitical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience. Blood 126(23):3225, 2015. e-Pub 2015.
157. Sasaki K, Shah N, Bashir Q, Hosing C, Popat U, Nieto Y, Parmar S, Shah J, Weber D, Weissinger D, Thomas S, Orlowski R, Champlin R, Qazilbash M. Outcome of Patients with Light Chain Multiple Myeloma Compared to lgG/IgA Myeloma after Autologous Stem Cell Transplant. Blood 126(23):3194, 2015. e-Pub 2015.
158. Mehta R, Saliba R, Chen J, Rondon G, Hammerstrom A, Alousi A, Qazilbash M, Bashir Q, Ahmed S, Popat U, Hosing C, Khouri I, Shpall E, Champlin R, Ciurea S. Post-Transplantation High Dose Cyclophosphamide As Gvhd Prophylaxis in 9/10 HLA-Matched Unrelated Donors Hematopoietic Stem Cell Transplantation. Blood 126(23):3135, 2015. e-Pub 2015.
159. Nieto Y, Valdez B, Thall P, Wei W, Jones R, Hosing C, Ahmed S, Popat U, Shpall E, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Hagemeister F, Champlin R, Andersson B. Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma. Blood 126(23):1992, 2015. e-Pub 2015.
160. Popat U, Ray G, Bassett R, Poon M, Valdez B, Konoplev S, Ahmed S, Alousi A, Andersson B, Bashir Q, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash M, Rezvani K, Shah N, Shpall E, Champlin R. Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial. Blood 126(23):738, 2015. e-Pub 2015.
161. Gaballa S, Ge I, El Fakih R, Brammer J, Wang S, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Al-Atrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall E, Khouri I, Champlin R, Ciurea S. Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation. Blood 126(23):152, 2015. e-Pub 2015.
162. Claussen CM, Chuang T, Shah J, Lee H, Shah N, Patel KK, Bashir Q, Parmar S, Thomas S, Qazilbash M, Davis RE, Neelapu SS, Weber D, Orlowski RZ, Feng L, Manasanch EE. Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. Blood 126(23):5390, 2015. e-Pub 2015.
163. Khouri I, Sui D, Turturro F, Erwin W, Bassett R, Korbling M, Valverde R, Ahmed S, Alousi A, Anderlini P, Bashir Q, Ciurea S, Oran B, Olson A, Popat U, Patel K, Qazilbash M, Fanale M, Fayad L, Nastoupil L, Westin J, Gulbis A, Medeiros J, Young K, Jessop A. In-Vivo Purging with Rituximab (R) Followed by Z/Beam vs Beam/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. Blood 126(23):3192, 2015. e-Pub 2015.
164. Shah J, Feng L, Weber D, Thomas S, Wang M, Turturro F, Qazilbash M, Shah N, Bashir Q, Popat U, Manasanch E, Munoz S, Landry A, Mendoza K, Nieto Y, r C, Orlowski R. Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologus Stem Cell Transplant in Patients with Multiple Myeloma. Blood 126(23):3155, 2015. e-Pub 2015.
165. Shah N, Li L, Kaur I, McCarty J, Yvon E, Shaim H, Muftuoglu M, Liu E, Sobieski C, Orlowski R, Cooper L, Lee D, Parmar S, Cao K, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, McNiece I, Qazilbash M, Champlin R, Rezvani K, Shpall E. Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study. Blood 126(23):929, 2015. e-Pub 2015.
166. Cornelison A, Saliba R, Ahmed S, Nieto Y, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Shpall E, Champlin R, Qazilbash M. Autologous Hematopoietic Stem Cell Transplantation (Auto-HCT) for Multiple Myelomja (MM) in the Inpatient (Inpt_ vs Outpatient (Outpt) Settings: Impact of Hematopoietic Stem Cell Comorbidity Index (HCT-CI). Biology of Blood and Marrow Transplantation, 2015. e-Pub 2015.
167. Brammer J, Khouri I, Gaballa S, Ledesma C, Anderlini P, Andersson B, Popat U, Bashir Q, Hosing C, Champlin R, Ciurea S. Safety and Efficacy of Non-Myeloablative (NMA) Melphalan-Based Conditioning for Haploidentical Allogeneic Stem Cell Transplantation (HaploSCT) in Patients with Advanced Lymphoma. Biology of Blood and Marrow Transplantation 21(Suppl 2):S195-196, 2015. e-Pub 2015.
168. Sasaki K, Saliba R, Lu G, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G. Outcome of Patients with Multiple Myeloma with t(4:14) after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation:S202-203, 2015. e-Pub 2015.
169. Badar T, Parmar S, Cornelison A, Shah N, Bashir Q, Patel K, Hosing C, Popat U, Champlin R, Qazilbash M. Outcome of Patients with Systemic Light Chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. Biology of Blood and Marrow Transplantation 21(Suppl 2):S130, 2015. e-Pub 2015.
170. Popat U, Saliba R, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Olson A, Parmar S, Shah N, Shpall E, Qazilbash M, Andersson B, Champlin R. Cytogenetics and Blast Count Determine Tranpslant Outcomes in Advanced AML. Biology of Blood and Marrow Transplantation:S304, 2015. e-Pub 2015.
171. Shah J, Feng L, Manasanch E, Weber D, Thomas S, Turturro F, Alexanian R, Shah N, Popat U, Nieto Y, Bashir Q, Qazilbash M, Champlin R, Orlowski R. Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. Blood 124(21):33, 2014. e-Pub 2014.
172. Oran B, Rima S, Andersson B, de Lima M, Popat U, Khouri I, Kebriaei P, Bashir Q, Ahmed S, Shpall E, Champlin R, Rondon G. Improved Progression-Free Survival with Miimal Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Hematological Malignancy. Blood 124(21):2533, 2014. e-Pub 2014.
173. Shah N, Thall P, Fox P, Bashir Q, Shah J, Parmar S, Kebriaei P, Nieto Y, Popat U, Hosing C, Pael K, Lin P, Shpall E, Orlowski R, Champlin R, Qazilbash M. Phase I/II Trial of Lenalidomide and High Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma. Blood 124(21):3981, 2014. e-Pub 2014.
174. Ahmed S, Shpall E, Gulbis A, Jones R, Martinez C, Rondon G, Rezvani K, Oran B, Olson A, Shah N, Parmar S, Popat U, Am A, Nieto Y, Hosing C, Bashir Q, Kebriaei P, Qazilbash M, Champlin R, Mulanovich V. Assessment of Incidence Toxoplasma Gondii Infection and Outcomes in Allogeneic Stem Cell Patients. Blood 124(21):1187, 2014. e-Pub 2014.
175. Williams L, Qazilbash M, Shi Q, Shah N, Bashir Q, Champlin R, Popat U, Kebriaei P, Parmar S, Limaye A, Cleeland C. Symptom Burden of Busulfan + Melphalan Versus Melphalan Alone for Multiple Myeloma. Blood 124(21):1277, 2014. e-Pub 2014.
176. Mian I, Milton D, Popat U, Shah N, NIeto Y, Kebriaei P, Parmar S, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Effect of Timing and Duration of Maintenance Lenalidomide in Myeloma Patients after Autologous Stem Cell Transplantations. Blood 124(21):194, 2014. e-Pub 2014.
177. Popat U, Fox P, Bassett R, Chen J, Valdez B, Kawedia J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Hosng C, Jones R, Kebriaei P, Khouri I, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash M, Shah N, Shpall E, Andersson B, Champlin R. Myeloablative Timed Sequential Busulfan is Safe in Older Patients. Blood 124(21):3859, 2014. e-Pub 2014.
178. Pingali S, Milton D, Popat U, Hosing C, Bashir Q, Alousi A, Jones R, Nieto Y, Kebriaei P, Qazilbash M, Andersson B, Shpall E, Khouri I, Champlin R, Ciurea S. Transplant Outcomes of 9/10 HLA Matched Unrelated Donors (MUD) Treated with Post-Transplant Cyclophosphamide for Prevention of Graft Versus Host Disease. Blood 124(21):2486, 2014. e-Pub 2014.
179. Bock F, Lu G, Shah N, Bashir Q, Patel K, Popat U, Hosing C, Gaballa S, Korbling M, Delgado R, Rondon G, Orlowski R, Shah J, Manasanch E, Champlin R, Qazilbash M. Clinical Characteristics and Outcomes in Patients with Multiple Myeloma and CKS1B Gene Gain/Amplification after Autologous Stem Cell Transplantation. Blood 124(21):2521, 2014. e-Pub 2014.
180. Pingali S, Milton D, di Stasi A, Patel R, Kebriaei P, Popat U, Alousi A, Anderlini P, Qazilbash M, Hosing C, Rezvani K, Bashir Q, Oran B, Shpall E, Khouri I, Champlin R, Ciurea S. Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning - Mature Results from a Single Center. Biology of Blood and Marrow Transplantation 20(2 Supplement 1):S40, 2014. e-Pub 2014.
181. Qazilbash M, Thall P, Fox P, Shah N, Bashir Q, Shah J, Parmar S, Kebriaei P, Nieto Y, Dinh Y, Popat U, Hosing C, Lin P, Shpall E, Orlowski R, Champln R. Phase I/II Trial of Lenalidomide and High-Dose Melphalan As Preparative Regimen for Relapsed Myeloma. Biology of Blood and Marrow Transplantation 20(2 Supplement 1):S47, 2014. e-Pub 2014.
182. Biritxinaga L, Jauch S, Popat U, Shafi M, Shah N, Bashir Q, Dinh Y, Hosing C, Champlin R, Qazilbash M. Impact of Hepatitis B Core Antibody (HBcAb) Seropositivity on the Outcome of High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Tranpslantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation 20(2 Supplement 1):S46, 2014. e-Pub 2014.
183. El Fakih R, Nieto Y, Fox P, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Popat U, Ahmed S, Shah J, Orlowski R, Dinh Y, Champlin R, Qazilbash M, Bashir Q. Autologous Stem Cell Transplantation in dialysis-dependent myeloma patients. Journal of Clinical Oncology 32(15 (Supplement )), 2014. e-Pub 2014.
184. Qazilbash M, Thall P, Fox P, Kebriaei P, Bashir Q, Shah N, Andersson B, Nieto Y, Baldez B, Parmar S, Dinh Y, Hosing C, Popat U, Shah J, Orlowski R, Champlin R. Randomized Phase III Trial of Busulfan Plus Melphalan versus Melphalan alone for Multiple Myeloma. Journal of Clinical Oncology 32(15 Supplement), 2014. e-Pub 2014.
185. Kongtim P, Qazilbash A, Shah J, Orlowski R, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Parmar S. Autologous Stem Cell Transplantation Improves Survival for High Risk Cardiac Amyloidosis. Blood 122(21):3341, 2013. e-Pub 2013.
186. Lichtiger B, Alousi A, Ahmed S, Anderlini P, Andersson B, Bashir Q, Ciurea S, Jones R, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Shpall E, Champlin R, Popat U. Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Cell Transplantation is Associated with Severe Pancytopenia. Blood 122(21):5449, 2013. e-Pub 2013.
187. Mohite S, Baladandayuthapani V, Thomas S, Weber D, Wang M, Alexanian R, Qazilbash M, Popat U, Champlin R, Shah N, Bashir Q, Parmar S, Nieto Y, Ahmed S, Orlowski R, Shah J. Circulating Plasma Cells By Routine Complete Blood Count Identify Patients with Similar Outcome as Plasma Cell Leukemia. Blood 122(21):5356, 2013. e-Pub 2013.
188. Popat U, Oran B, Hosing C, Kebriaei P, Rezvani K, Parmar S, Shah N, Bollard C, Molldrem J, Nieto Y, Andersson B, Alousi A, Jones R, Cooper L, Qazilbash M, Bashir Q, Ahmed S, Bosque D, Chen J, McCarty J, Rondon G, Munsell M, McNiece I, Kaur I, Yvon E, Annandale K, Olchesky S, de Lima M, Champlin R, Miller L, Paradiso L, Koh L, Zweidler-McKay Z, Shpall E. Ex Vivo Fucosylation of Cord Blood Accelerates Neutrophil and Platelet Engraftment. Blood 122(21):691, 2013. e-Pub 2013.
189. Pingali S, Saliba R, Smith V, Maadani F, Adekola K, Popat U, Qazilbash M, Bashir Q, Khouri I, Kebraei P, Ciurea S, Anderlini P, Shah N, Nieto Y, Champlin R, Hosing C. Number of Apheresis Days to Reach Target Stem Cell Dose May Be a Predictor of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia. Blood 122(21):4515, 2013. e-Pub 2013.
190. Patel K, Feng L, Oki Y, Qazilbash M, Muzzafar T, Weber D, Fowler N, Popat U, Thomas S, Fanale M, Nieto Y, Shah N, Bashir Q, Hagemeister F, Orlowski R, Shah J. Plasmablastic Lymphoma: 28 Patient Single Institution Experience. Blood 122(21):4310, 2013. e-Pub 2013.
191. Adekola K, Bashir Q, Shah N, Pingali S, Parmar S, Popat U, Hosing C, Champlin R, Qazilbash M. Characteristics of Multiple Myeloma Patients with 6-Year or Longer Progression-Free Survival After a Single Autologous Transplant. Blood 122(21):3366, 2013. e-Pub 2013.
192. Nusrat M, Kazmi S, Cornelison A, Kebriaei P, Nieto Y, Oran B, Orlowski R, Parmar S, Popat U, Shah J, Shah N, Champlin R, Qazilbash M, Bashir Q. Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated with High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. Blood 122(21):3358, 2013. e-Pub 2013.
193. Khouri I, Saliba R, Challagundla P, Ledesma C, Korbling M, Gulbis A, Guillermo-Pacheco M, Ahmed S, Anderlini P, Bashir Q, Oran B, Ciurea S, Hosing C, Kebriaei P, Popat U, Jabbour E, Champlin R, Jorgensen J. Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results ncluding Minimal Residual Disease Analysis. Blood 122(21):3349, 2013. e-Pub 2013.
194. Nieto Y, Shah N, Popat U, Jones R, Bashir Q, Bassett R, Valdez B, Andersson B, Parmar S, Orlowski R, Shah J, Thomas S, Wang M, Champlin R, Qazilbash M. High-Dose Gemcitabine Combined with Busulfan and Melphalan (Gem/Bu/Mel) with Autologous Stem Cell-Transplant (ASCT) in Refractory and Relapsed Myeloma. Blood 122(21):3346, 2013. e-Pub 2013.
195. Oran B, Poon M, Chen J, Rondon G, Ahmed S, Andersson B, Bashir Q, Ciurea S, Hosing C, Parmar S, Qazilbash M, Popat U, Nieto Y, Alousi A, Jones R, Rezvani K, de Lima M, Shpal E, Champlin R, Kebriaei P. Comparable Outcomes after Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) with First Complete Remission (CR). Blood 122(21):2142, 2013. e-Pub 2013.
196. Ahmed S, Di Stasi A, Shpall E, Khouri I, Alousi A, Ciurea S, Bashir Q, Qazilbash M, Jones R, Nieto Y, Parmar S, Kebriaei P, Shah N, Rezvani K, Hosing C, Oran B, Andreeff M, Anderlini P, Andersson B, Champlin R, Popat U. Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant. Blood 122(21):2083, 2013. e-Pub 2013.
197. Shah J, Baladandayuthapani V, Weber D, Thomas S, Alexanian R, Wang M, Qazilbash M, Champlin R, Shah N, Bashir Q, Popat U, Nieto Y, Ahmed S, Parmar S, Orlowski R. Phase II Study of the Combination of MLN 9708 with Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood 122(21):1983, 2013. e-Pub 2013.
198. Nieto Y, Thall P, Valdez B, Hosing C, Ahmed S, Jones R, Shah N, Anderlini P, Qazilbash M, Popat U, Bashir Q, Shpall E, Alousi A, Kebriaei P, Fox P, Bassett R, Chancoco C, Oki Y, Fanale M, Fowler N, Hagemeister F, Romaguera J, Champlin R, Andersson B. Vorinostat (SAHA) Combined with High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphomas. Blood 122(21):2095, 2013. e-Pub 2013.
199. Ghobadi A, Hamdi A, Kongtim P, Milton D, Alousi A, Anderlini P, Ciurea S, Oran B, Khouri I, Parmar S, Qazilbash M, Kebriaei P, Popat U, Rezvani K, Chemaly R, Shpall E, Champlin R, Qaiser B. The Effect of CMV Reactivatio on Relapse and Survival in Patients with AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT). Blood 122(21):4531, 2013. e-Pub 2013.
200. Pingali S, Denai M, An DS, Kebriaei P, Popat U, Alousi A, Anderlini P, Parmar S, Hosing C, Andersson B, Bashir Q, Ahmed S, Oran B, Shpall E, Khouri I, Konopleva M, Al-atrash A, Champlin R, Ciurea S. Haploidentical Transplantation for Patients with Advanced Hematologic Malignancies with Melphalan-Based Conditioning - Interim Results form a Phase II Clinical Trial. Blood 122(21):4523, 2013. e-Pub 2013.
201. Jimenez A, de Lima M, Popat U, Borthakur G, Abruzzo L, Andersson B, Garcia-Manero G, Jabbour E, Chem J, Bashir Q, Ciurea S, Kebriaei P, Ahmed S, Khouri I, Kongtim P, Qazilbash M, Rondon G, Shpall E, Champlin R, Oran B. Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML). Journal of Clinical Oncology 31(15), 2013. e-Pub 2013.
202. Cornelison A, Dinh Y, Ahmed S, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Shah J, Shpall E, Champlin R, Qazilbash M. Younger (<50 years) multiple myeloma (MM) patients (pts) treated with novel agents and autologous haematopoietic stem cell transplantation (auto-HCT) have longer overall survival than older pts (> 50 years). Bone Marrow Transplantation 48(Supplement 2):S205, 2013. e-Pub 2013.
203. Parmar S, Howell J, Wang M, Khan M, Bashir Q, Shah N, Shah J, Popat U, Dinh Y, Giralt S, Champlin R, Orlowski R, Qazilbash M. High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation 19(2 Supplement 2):S125, 2013. e-Pub 2013.
204. Howell J, Parmar S, Bashir Q, Shah N, Hosing C, Popat U, Cornelison M, Champlin RE, Qazilbash. Fluid Retention and Weight Gain During Peripheral Blood Hematopoietic Stem Cell Mobilization in Light Chain Amyloidosis. Biolog of Blood and Marrow Transplantation 19(Suppl 2):S183-S184, 2013. e-Pub 2013.
205. Howell J, Parmar S, Bashir Q, Shah N, Hosing C, Popat U, Cornelison M, Champlin R, Qazilbash M. Fluid Retentin and Weight Gain During Peripheral Blood Hematopoietic Stem Cell Mobilization in Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation 19(2 Supplement 2):S183, 2013. e-Pub 2013.
206. Cornelison A, Parmar S, Bashir Q, Shah N, Howell J, Hosing C, Popat U, Champlin R, Qazilbash M. Autologous Hematopoietic Stem Cell Transplantation in Light Chain Amyloidosis (AL) With Renal Involvement. Biology of Blood and Marrow Transplant 19(2 Supplement 2):S234, 2013. e-Pub 2013.
207. Dinh Y, Sharma M, Shah N, Bashir Q, Parmar S, Hosing C, Popat U, Champlin R, Qazilbash M. Bortezomib with High-Dose Melphalan, Arsenic Trioxide, and Ascorbic Acid in a Preparative Regimen for Multiple Myeloma: 5 Year Follow Up. Blood 122(21):5547. e-Pub 2013.
208. Aung F, Lichtiger R, Rondon G, Alousi A, Ahmed S, Andersson B, Bashir Q, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Betual O, Parmar S, Qazilbash M, Shah N, Shpall E, Champlin R, Popat U. Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopoenia. Haematologica 100(Supplement 1), 2013. e-Pub 2013.
209. Shah J, Orlowski R, Thomas S, Alexanian R, Wang M, Qazilbash M, Popat U, Parmar S, Shah N, Bashir Q, Champlin R, Weber D. Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma. Blood 120(21):75, 2012. e-Pub 2012.
210. Patel K, Orlowski R, Shah N, Bashir Q, Parmar S, Dinh Y, Rondon G, Giralt S, Champlin R, Qazilbash M. Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Blood 120(21):3115, 2012. e-Pub 2012.
211. Patel K, Saliba R, Shah N, Bashir Q, Thomas S, Dinh Y, Hosing C, Popat U, Parmar S, Giralt S, Champlin R, Qazilbash M. Autologous Stem Cell Transplantation in Waldenstrom's Macroglobulinemia. Blood 120(21):4533, 2012. e-Pub 2012.
212. Shah J, Weber D, Thomas S, Alexanian R, Wang M, Qazilbash M, Parmar S, Shah N, Bashir Q, Popat U, Hilder B, Orlowski R. Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520+Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood 120(21):4082, 2012. e-Pub 2012.
213. Shah J, Thomas S, Weber D, Wang M, Alexanian R, Qazilbash M, Bashir Q, Parmar S, Shah N, Popat U, Orlowski R. Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood 120(21):4081, 2012. e-Pub 2012.
214. Gul Z, Khan H, Bashir Q, Shah N, Parmar S, Dinh Y, Hosing C, Popat U, Kebriaei P, Anderlini P, Shpall E, Giralt S, Champlin R, Qazilbash M. EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma. Blood 120(21):3094, 2012. e-Pub 2012.
215. Jabbour E, Kantarjian H, Oran B, Ravandi F, Ghanem H, Khouri I, Garcia-Manero G, Mathisen M, Bashir Q, Saliba R, Khouri M, Pierce S, Brandt M, Champlin R, de Lima M. Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Mueloid Leukemia (AML) with Chromosome Seven Abnormalities. Blood 120(21):2029, 2012. e-Pub 2012.
216. Parmar S, Howell J, Wang M, Khan M, Bashir Q, Shah J, Shah N, Popat U, Giralt S, Orlowski R, Qazilbash M. High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis: 14 Year Follow Up. Blood 120(21):750, 2012. e-Pub 2012.
217. Gul Z, Bashir Q, Nieto Y, Sherwani N, Parmar S, Shah N, Dinh Y, Hosing C, Popat U, Kebriaei P, Shpall E, Giralt S, Champlin R, Qazilbash M. Cardiac Toxicity After High-Dose Melphlan and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Blood 120(21):2027, 2012. e-Pub 2012.
218. Khan D, Patel K, Thomas S, Weber D, Delasalle K, Hosing C, Popat U, Bashir Q, Shah N, Parmar S, Champlin R, Qazilbash M. Feasibility of Hematopoietic Stem Cell Collection and Cryopreservation in Waldenstrom's Macroglobulinemia. Blood 120(21):4128, 2012. e-Pub 2012.
219. Khouri I, Saliba R, Turturro F, Korbling M, Ledesma C, Rondon G, Alousi A, Anderlini P, Bashir Q, Ciurea S, Hosing C, Popat U, Charafeddine Y, Oki Y, Fayad L, Champlin R. Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients who are not eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation. Blood 120(21):4157, 2012. e-Pub 2012.
220. Ahmed S, Saliba R, de Lima M, Fisher T, Rondon G, Kebriaei P, Alousi A, Hosing C, Bashir Q, Andersson B, Champlin R. International Consensus Criteria for Tyrosine Kinase Inhibitor Response and Outcome of Allogeneic Stem Cell Transplantation for CML. Blood 120(21):1997, 2012. e-Pub 2012.
221. Bashir Q, Parmar S, Dinh Y, Qureshi S, Rondon G, Popat U, Nieto Y, Jones R, Champlin R, Qazilbash M, Shah N. Association of Bone Marrow Plasma Cell Infiltration Pre-Auto Transplant with Adverse Outcomes in Multiple Myeloma. Journal of Clinical Oncology, 2012. e-Pub 2012.
222. Nieto Y, Jones R, Liu P, Anderlini P, Popat U, Andersson B, Shpall E, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Chancoco C, Bashir Q, Ciurea S, Parmar S, Champlin R. Comparison of Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) with Beam and Busulfan/Melphalan (Bu/Mel) in Concurrent Cohorts of Refractory Hodgkin's Lymphoma (HL) Patients Receiving an Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation 18(2 Supplement 2):S206, 2012. e-Pub 2012.
223. Ahmed S, Dinh Y, Rondon G, Andersson B, Jones R, Bashir Q, Shah N, Popat U, Champlin R, Qazilbash M, Kebriaei P. Comparison of Busulfan + Melphalan to Melphalan to Melphalan 200 MG/M2 as Preparative Regimen for Autologous Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation 18(2 Supplement 2):S251, 2012. e-Pub 2012.
224. Farhan S, Lin H, Baladandayuthapani V, Shah N, Bashir Q, Hosing C, Popat U, Parmar S, Dinh Y, Qureshi S, Rondon G, Giralt S, Champlin R, Qazilbash M. Outcome of Patients with Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 18(2 Supplement 2):S248, 2012. e-Pub 2012.
225. Nieto Y, Jones R, Popat U, Andersson B, Valdez B, Thall P, Shpall E, Chancoco C, Alousi A, Anderlini P, Hosing C, Qazilbash M, Bashir Q, Kebriaei P, Khouri I, Ciurea S, Parmar S, Rondon G, Champlin R. Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) is a new High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin's Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT). Biology of Blood and Marrow Transplantation 18(2 Supplement 2):S206, 2012. e-Pub 2012.
226. Khouri I, Saliba R, Valverde R, Samuels B, Korbling M, Alousi A, Anderlini P, Bashir Q, de Lima M, Hosing C, Kebriaei P, Nieto Y, Popat U, Qazilbash M, Neelapu S, Fowler N, Samaniego F, Wang L, Champlin R, Macapinlac H. Nonmyeloablative Allogeneic Stem Cell Transplantation with/or without 90yttrium Ibritumomab Tiuxetan (o0YIT) is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results. Blood 118(21):662, 2011. e-Pub 2011.
227. Ahmed S, Lin H, Baladandayuthapani V, Khan M, Lu G, Rondon G, Qureshi S, Dinh Y, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Giralt S, Orlowski R, Shah J, Champlin R. Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologus Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Blood 118(21):333, 2011. e-Pub 2011.
228. Qazilbash M, Thall P, Liu P, Orlowski R, Bashir Q, Shah N, Kebriaei P, Parmar S, Jones R, Hosing C, Popat U, Dinh Y, Rondon G, Shah J, de Lima M, Champlin R, Giralt S. A Randomized Phase II Trial of Fludarabine/Melphalan 140 Vs Fludarabine/Melphalan 100 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Blood 118(21):4108, 2011. e-Pub 2011.
229. Patel K, Orlowski R, Shah N, Bashir Q, Dinh Y, Rondon G, Giralt S, Champlin R, Qazilbash M. Durable Responses with Autologous Hematopoietic Stem Cell Transplantation in Patients with POEMS Syndrome. Blood 118(21):4522, 2011. e-Pub 2011.
230. Kazmi S, Lu G, Shah N, Bashir Q, Parmar S, Orlowski R, Shah J, Hosing C, Popat U, Dinh Y, Qureshi S, Rondon G, Giralt S, Champlin R, Qazilbash M. A Comparative Study of the Outcome of High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with High-Risk or Standard-Risk Myeloma Treated Concurrently. Blood 118(21):4156, 2011. e-Pub 2011.
231. Shah N, Bashir Q, Parmar S, Dinh Y, Qureshi S, Rondon G, Popat U, Nieto Y, Jones R, Champlin R, Qazilbash M. Increased Bone Marrow Plasma Cell Infiltration Pre-Transplant Is Associated with Worse Outcomes in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation for Multiple Myeloma. Blood 118(21):4135, 2011. e-Pub 2011.
232. Farhan S, Lin H, Baladandayuthapani V, Shah N, Bashir Q, Hosing C, Popat U, Parmar S, Dinh Y, Qureshi S, Rondon G, Giralt S, Champlin R, Qazilbash M. Response Before Autologous Hematopoietic Stem Cell Transplantation Is An Important Predictor of Outcome in Multiple Myeloma. Blood 118(21):4119, 2011. e-Pub 2011.
233. Beitinjaneh A, Saliba R, Okoroji G, Korbling M, Alousi A, Popat U, Anderlini P, Bashir Q, Andersson B, Kebriaei P, Hosing C, Qazilbash M, Fanale M, Pro B, Champlin R, Khouri I. Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M. D. Anderson Cancer Center Experience. Blood 118(21):4118, 2011. e-Pub 2011.
234. Nieto Y, Thall P, Andersson B, Popat U, Anderlini P, Valdez B, Shpall E, Qazilbash M, Alousi A, Chancoco C, Hosing C, Kebriaei P, Bashir Q, Shah N, Khouri I, Ciurea S, McMullin B, Rondon G, Champlin R, Jones R. High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies. Blood 118(21):3083, 2011. e-Pub 2011.
235. Ahmed S, Chiattone A, Jones R, Shpall E, Farhan S, Rondon G, Nieto Y, Bashir Q, Chen J, Khouri I, Kebriaei P, Anderlini P, Champlin R, de Lima M. Allogeneic Stem Cell Transplantation for CML in Second Chronic Phase After Blast Crisis in the Tyrosine Kinase Inhibitor Era. Blood 118(21):2039, 2011. e-Pub 2011.
236. Ahmed S, Dinh Y, Qureshi S, Rondon G, Bashir Q, Parmar S, Avery T, Orlowski R, Champlin R, Qazilbash M, Shah N. Survival Disparities Between African-American and Caucasian Patients Treated with Autologous Stem Cell Transplantation for Multiple Myeloma are Eliminated in the Era of Novel Therapeutics. Blood 118(21):2017, 2011. e-Pub 2011.
237. Bashir Q, Wei W, Chiattone A, Rondon G, Parmar S, Shah N, Booc E, Dinh Y, Qureshi S, Shah F, Orlowski R, Weber D, Champlin R, Giralt S, Qazilbash M. Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients Age 70 Years and Older. Biology of Blood and Marrow Transplantation 17(2 Supplement 2):S178, 2011. e-Pub 2011.
238. Beitinjaneh A, Shah N, Bashir Q, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin R, Giralt S, Qazilbash M. Donor-Lymphocyte Infusion in Patients with Persistent or recurrent Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 17(2 Supplement 2):S340, 2011. e-Pub 2011.
239. Bashir Q, Wei W, Chiattone A, Rondon G, Parmar S, Shah N, Booc E, Dinh Y, Qureshi S, Shah F, Orlowski R, Weber D, Champlin R, Giralt S, Qazilbash M. Allogeneic Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation 17(2 Supplement 2):S177, 2011. e-Pub 2011.
240. Sharma M, Thall P, Shah N, Bashir Q, Parmar S, Wang M, Shah J, Orlowski R, Weber D, Thomas S, Hosing C, Anderlini P, Kebriaei P, Popat U, Champlin R, Giralt S, Qazilbash M. Randomized Phase II Trial of a Combination of Bortezemib with High Dose Melphalan, Arsenic Trioxide and Ascorbic Acid. Haematologica 96((s1)):S82, 2011. e-Pub 2011.
241. Parmar S, Khan M, Rondon G, Shah N, Bashir Q, Tung S, Shah J, Weber D, Orlowski R, Giralt S, Champlin R, Qazilbash M. Outcome of High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplant in Myeloma Associated with Amyloidosis. Haematologica 96(s1):S75, 2011. e-Pub 2011.
242. Bashir Q, Wei W, Rondon G, Dinh Y, Parmar S, Shah N, Lu G, Shah J, Orlowski R, Majid A, Giralt S, Champlin R, Qazilbash M. Impact of Cytogenetics on the Outcomes in Multiple Myeloma Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Haematologica 96(s1):S108, 2011. e-Pub 2011.
243. Beitinjaneh A, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin R, Giralt S, Qazilbash M. Durable Response After Donor Lymphocyte Infusion in Patients with Residual Multiple Myeloma After Allogeneic Hematopoietic Stem Cell Transplantation. Haematologica 96(s1):S95, 2011. e-Pub 2011.
244. Bashir Q, Wei W, Chiattone A, Rondon G, Parmar S, Shah N, Booc E, Yvonne D, Sofia Q, Shah J, Orlowski R, Weber D, Champlin R, Giralt S, Qazilbash M. Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma. Blood 116(21):4569, 2010. e-Pub 2010.
245. Parmar S, Khan M, Rondon G, Shah N, Bashir Q, Tung S, Shah J, Weber D, Orlowski R, Giralt S, Champlin R, Qazilbash M. High Dose Melphalan with Autologous Stem Cell Transplantation Overcomes Poor Prognosis of Primary Amyloidosis. Blood 116(21):1350, 2010. e-Pub 2010.
246. Shah J, Orlowski R, Alexanian R, Wang M, Thomas S, Qazilbash M, Parmar S, Shah N, Bashir Q, Popat U, Weber D. Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Blood 116(21):1948, 2010. e-Pub 2010.
247. Parmar S, Khan M, Rondon G, Shah N, Bashir Q, Tung S, Shah J, Weber D, Orlowski R, Giralt S, Champlin R, Qazilbash M. Outcome of High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplant In Myeloma Associated with AL Amyoidosis. Blood 116(21):2400, 2010. e-Pub 2010.
248. Chiattone A, Saliba R, Andersson B, Giralt S, Sharma M, Rondon G, Kebriaei P, Hosing C, Popat U, Parmar S, Alatrash G, Bashir Q, Chen J, Yuen C, Chiattone V, Champlin R, de Lima M. Treatment of AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Low-Dose Azacitidine (AZA). Blood 116(21):3445, 2010. e-Pub 2010.
249. Sharma M, Ravandi F, Ciattone A, Kebriaei P, Popat U, Giralt S, Bashir Q, Qazilbash M, Nieto Y, Yuen C, Parmar S, Kantarjian H, Cortes J, Kadia T, Borthakur G, Champlin R, de Lima M. Treatment of FLT3-ITD Positive AML Relapsing After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) with Sorafenib. Blood 116(21):3471, 2010. e-Pub 2010.
250. Bashir Q, Wei W, Chiattone A, Rondon G, Parmar S, Shah N, Booc E, Yvonne D, Sofia Q, Shah J, Orlowski R, Weber D, Champlin R, Giralt S, Qazilbash M. Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients Age 70 Years and Older. Blood 116(21):4576, 2010. e-Pub 2010.
251. Chiattone A, Andersson B, Bashir Q, Landau D, Rondon G, Nieto Y, Al-Altrash G, Giralt S, Champlin R, De Lima M. Treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapsing after allogeneic hematopoietic cell transplantation (HCT). Journal of Clinical Oncology 28(15S):496s, 2010. e-Pub 2010. PMID: 21767516.
252. Bashir Q, Andersson B, Silva L, Rondon G, Chiattone A, Hosing C, Fernandez-Vina M, Giralt S, Champlin R, de Lima M. Treatment of acute myeloid leukemia (AML) in first remission (CR1) with unrelated donor (UD) allogeneic hematopoietic cell transplantation (HCT). Journal of Clinical Oncology 28(15S):495S, 2010. e-Pub 2010.
253. Bashir Q, Thall P, Hosing C, Mendoza F, Han E, Wang M, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin R, Giralt S, Qazilbash M. Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of Frist Autographt in Patients with Multiple Myeloma. Blood 114(22):1186, 2009. e-Pub 2009.
254. Bashir Q, Bemis L, Robinson W, Liu B, Wang S, Amato C, Riley E, Lee C. Role of MicroRNAs in Resistance to Dexamethasone in Multiple Myeloma Cell Lines. Blood 112(11):3680, 2008. e-Pub 2008.
255. Kabos P, Bashir Q, Chen R, Lindenfeld J, Myint H, Lee C. B-ype Natriuretic Peptide (BNP) and Mitral Velcity E/A Ratio (MV E/A) Are Two Important Noninvasive Functional Indices of Cardiac AL Amyloidosis. Blood 110(11):4773, 2007. e-Pub 2007.
256. Hopkins T, Floyd JD, Mirza IA, Lobins RL, Bashir Q, Shahabad N. Pegfilgrastim in Autoimmune Neutropenia. Blood 104(11):3790, 2004. e-Pub 2004.

Book Chapters

1. Jallouk, AP, Bashir, Q. Hematopoietic Cell Transplantation in Light Chain Amyloidosis, 331-340, 2023.
2. Champlin, RE, Bashir, Q. Hematopoietic Transplantation, 3-16, 2023.
3. Bashir Q, Shpall E, Champlin R. Hematopoietic Cell Transplantation. In: Holland-Frei Cancer Medicine. 10th, 2021.
4. Mir, MA, Bashir, Q. Autologous hematopoietic stem cell transplantation for non-hodgkin lymphoma, 203-208, 2019.
5. Bashir, Q, Champlin, RE. Hematopoietic Stem Cell Transplantation, 485-492.e2, 2014.
6. Bashir Q, Champlin R. In: Hematopoietic Stem Cell Transplantation. 5th. Elsevier Churchill Livingston, 485-492, 2014.

Books (edited and written)

1. Bashir, Q, Shpall, E, Champlin, RE. Manual of Hematopoietic Cell Transplantation and Cellular Therapies, 2023.
2. Bashir, Q, Hamadani, M. Hematopoietic cell transplantation for malignant conditions, 2019.
3. Q Bashir Q, M Hamadani M. Hematopoietic Cell Transplantation for Malignant Conditions. Ed(s) 1. Dolores Meloni, 2019.

Letters to the Editor

1. Lee HC, Becnel MR, Feng L, Pasvolsky O, Murga A, Johnson RJ, Thomas SK, Bashir Q, Qazilbash MH, Steiner R, Iyer SP, Weber DM, Patel KK, Kaufman GP, Manasanch EE, Orlowski RZ. A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis. Am J Hematol, 2026.
2. Marcoux, C, Pasyar, S, Milton, D, Khan, HN, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Neupane, N, Lee, HC, Patel, K, Tang, G, Aljawai, YM, Kebriaei, P, Thomas, SK, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH, Pasvolsky, O. Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant. British Journal of Haematology 206: 763-765, 2025.
3. Malek, A, Al-Juhaishi, T, Milton, D, Ramdial, JL, Daher, M, Olson, AL, Srour, S, Al-Atrash, G, Oran, B, Mehta, RS, Khouri, IF, Bashir, Q, Shah, N, Ciurea, SO, Rondon, G, Maadani, F, Hosing, C, Marin, D, Kebriaei, P, Rezvani, K, Nieto, Y, Anderlini, P, Alousi, AM, Faisal, MS, Qazilbash, MH, Popat, UR, Champlin, RE, Shpall, E, Mulanovich, VE, Ahmed, S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone marrow transplantation 59: 699-704, 2024.
4. Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. British Journal of Haematology 201: e37-e41, 2023.
5. Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short NJ, Ravandi F, Champlin R, Shpall EJ, Kebriaei P. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. American journal of hematology 98: E35-E37, 2023.
6. Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RS. A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation. Haematologica 107: 2496-2500, 2022.
7. Kongtim P, Bittencourt M, Srour SA, Ramdial J, Rondon G, Chen J, Khouri I, Betul O, Popat U, Olson A, Bashir Q, Shpall EJ, Kebriaei P, Champlin RE, Ciurea SO. Haploidentical transplants for patients with graft failure after the first allograft. American journal of hematology 95: E267-E269, 2020.
8. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenström’s macroglobulinemia. Annals of Hematology 98: 2233-2235, 2019.
9. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. American journal of hematology 94: E72-E74, 2019.
10. Varma A, Saliba RM, Torres HA, Afrough A, Hosing C, Khouri IF, Nieto Y, Shah ND, Parmar S, Bashir Q, Ahmed S, Jones RB, Kebriaei P, Olson AL, Shpall EJ, Alousi AM, Qazilbash MH, Champlin RE, Popat U. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone marrow transplantation 51: 999-1001, 2016.
11. Cornelison AM, Saliba RM, Afrough A, Dinh Y, Nieto Y, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Shpall E, Champlin R, Qazilbash MH. Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement. Bone marrow transplantation 51: 307-309, 2016.
12. Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia 29: 1945-1948, 2015.
13. Gul Z, Bashir Q, Cremer M, Yusuf SW, Gunaydin H, Arora S, Slone S, Nieto Y, Sherwani N, Parmar S, Shah N, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Shpall EJ, Giralt SA, Champlin RE, Qazilbash MH. Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Leukemia and Lymphoma 56: 533-535, 2015.
14. Patel K, Nusrat M, Shah N, Bashir Q, Parmar S, Shah J, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MH. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone marrow transplantation 49: 465-466, 2014.
15. Mehta R, Di Stasi A, Andersson B, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall E. The Development of a Myeloablative Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. Clinical Lymphoma,Myeloma & Leukemia 14: e1-5, 2014.